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Abstract: The resurgence of research into phage biology and therapy is, in part, due to the increasing
need for novel agents to treat multidrug-resistant infections. Despite a long clinical history in Eastern
Europe and initial success within the food industry, commercialized phage products have yet to enter
other sectors. This relative lack of success is, in part, due to the inherent biological limitations of whole
phages. These include (but are not limited to) reaching target sites at sufficiently high concentrations
to establish an infection which produces enough progeny phages to reduce the bacterial population
in a clinically meaningful manner and the limited host range of some phages. Conversely, parallels
can be drawn between antimicrobial enzymes derived from phages and conventional antibiotics.
In the current article the biological limitations of whole phage-based therapeutics and their derived
antimicrobial enzymes will be discussed. In addition, the ability of more complex formulations to
address these issues, in the context of medical and non-medical applications, will also be included.
Keywords: bacteriophage; pharmacology; synergy; formulation; combination therapy; product
development
1. Introduction
Renewed interest in the clinical and non-clinical application of phages and their derived
antimicrobial enzymes has been stimulated by the need for new types of antibacterial agents to
combat the ongoing problem of antibiotic resistance [1–4]. Although phages are still often compared to
antibiotics, it is well established that they possess both advantages and disadvantages as therapeutic
agents. In general, it is accepted that antibiotic treatments result in higher levels of collateral damage
to pre-existing microflora due to their non-specific activities [5,6], while phage treatment minimizes
this damage [7–9]. Therapy based upon the application of whole phages has traditionally been utilized
in Eastern Europe to treat a variety of different infections ranging from diabetic foot ulcers to stomach
complaints. This type of treatment takes advantage of the lytic replication cycle of wholly-virulent
bacteriophages [10,11].
A limited number of whole phage-based products have found success as food additives within
Western markets and phage-derived enzymes show promising results, but they are yet to enter the
mainstream as human or veterinary therapeutics (Table 1) [12–15]. There are many obstacles that
need to be solved before phages can reach clinical settings and be widely applied in therapy. Many of
these issues are associated with the nature and variation of phages, which influences everything from
isolation and purification to potential formulation strategies. Each phage possesses unique properties
that may or may not be desirable for targeted therapy, e.g., narrow host ranges, pharmacological
criteria (burst sizes and latent period), and the ability to maintain bacterial killing in adverse conditions.
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There are also a number of factors regarding the bacterial host that must be considered, such as
the number of targeted bacterial cells, their metabolic state, and the presence of phage defense
mechanisms [16–19]. The vast complexity when these, and other factors, are combined makes it
difficult to construct a universal phage formulation for a particular condition that can provide optimal
phage efficacy while minimizing deleterious effects. These effects range from competition between
phages within a cocktail to clearance by the immune system [20–23].
Increased levels of knowledge about phage genomes and their function within lytic replication
has led to the identification of a number of phage derived proteins which have been shown to be
powerful antibacterial agents in their own right [24–28]. These proteins are often produced during
the latter stages of the phage replication cycle to aid in the release of newly-assembled phages from
the bacterial host and have predominantly focused on endolysins [29,30]. However, it should be
noted that other phage derived antimicrobial enzymes, including holins and spanins, have also been
investigated [24,31].
Adjuncts and excipients are components of pharmaceutical preparations that can increase the
activity of the main active ingredient when administered at the same time (e.g., the combination
of caffeine and paracetamol) which play an important role in pharmaceutical formulations [32,33].
In normal pharmaceuticals, these additional components play important roles within the final
formulations, ranging from increasing the shelf life of finished products to serving as binding agents,
such as alginates, which can hold finished formulations together to produce pills [34,35]. The selection
of appropriate adjunct compounds for each formulation is dependent on the nature of the therapy to be
developed and is thought to reduce the failure rate in novel drug development [36]. As there have been
reports of clinical successes of phage suspensions that presumably do not contain adjuncts, limited
attention has been given to the development of more complex phage-based formulations that combine
phages and additional pharmaceutical components. For therapies based upon whole phages or their
derived antimicrobial enzymes, the formulation of biologically-active components with additional
adjuncts may address a number of these factors.
The current review seeks to investigate the general issues associated with whole phage and phage
derived antimicrobial enzymes (in particular endolysins as these are the most widely studied) and how
they could be incorporated with compatible adjuncts for clinical and non-clinical applications. Areas
in which complex formulations could potentially enhance the overall efficacy of therapies will also be
highlighted. Although engineered phages and antimicrobial enzymes are also being investigated, they
will not form part of the current review.
Pharmaceuticals 2018, 11, 34 3 of 25
Table 1. Summary of commercially available whole phage and phage-derived antimicrobial enzyme. FDA: Food and Drug Administration, USA, USDA FSIS: United
States Department of Agriculture Food Safety and Inspection Service, GRAS: Generally Recognized as Safe, EPA: Environmental Protection Agency, USA.
Manufacturer Product Name Application Approval Status Reference
Whole Phage
Intralytix
ListShieldTM
Targets Listeria monocytogenes in food/food
processing
Complies with FDA food additive rules
[37]
USDA FSIS listed safe
EPA-registered
Health Canada approved
National Food Services of Israel approved
EcoShieldTM Targets E. coli 0157:H7 in food/food processing
FDA Cleared
[38]
Health Canada approved
National Food Service of Israel approved
USDA FSIS listed safe
SalmoFreshTM
Targets highly pathogenic Salmonella-serotypes
in food/food processing
USDA FSIS listed safe
[39]
GRAS for direct application
Health Canada approved
National Food Service of Israel approved
ShigaShieldTM Targets Shigella species in food/food processing GRAS for direct application [40]
OmniLytics AgriPhageTM Targets bacterial spot, bacterial speck andbacterial canker on tomato and pepper plants EPA registered [41]
Pherecydes Pharma
PhagoBurn Targets skin infections in burn wounds Phase 2 clinical trials [42,43]
PneumoPhage Targets Pseudomonas aeruginosa in acuterespiratory tract infections - [44]
Phosa Targets Staphylococcus aureus and epidermidis inbone infections - [45]
AmpliPhi Biosciences
Corporation
AB-SA01 Targets S. aureus
Expanded Access
[46]Phase 1 completed
AB-PA01 Targets Pseudomonas aeruginosa Expanded Access
Endolysin
Micreos Human Health StaphefektTM Endolysin that targets S. aureus and MRSA Interventional Clinical Trial [15,47,48]
ContraFect CF-301 Phage-derived lysin that targets S. aureus blood
stream infections
Completed Phase 1 clinical trials
[49]
Granted Fast Track Designation from FDA
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2. Compound Selection and Pre-Formulation Testing
In the development of pharmaceutical adjuncts and novel biocides, clearly established protocols and
legislation exist for determining safety and efficacy, both as individual compounds and also when part of
formulations, with requirements that vary by application (Table 2) [50]. For phage-derived antimicrobial
enzymes, the activity and host range could be easily assessed using pre-existing antibiotic susceptibility
testing methods [51,52]. However, there are currently multiple methods that can be used when determining
the activity of single whole phages [53–56]. Although these methods are based upon the ability of the
phage to produce plaques in a bacterial lawn, they have been shown to produce varying results [56], and it
is widely accepted that only purely-lytic phages should be utilized and that their inherent characteristics
(e.g., burst size, host range) should be considered for therapy [57,58], As such, it is essential that rapid, easy
to use, quantitative assays are developed which can differentiate between multiple phages.
Once the initial characterization of the phage or antimicrobial enzyme had been performed, and
prior to assessing the overall effects of a finished formulation, it would be necessary to know the
impact of any potential adverse or additive effects that adjunct compounds provide to the phages or
the derived antimicrobial enzymes themselves, as well as the impact upon the bacterial host [59,60].
Perhaps the most obvious concern would be a decrease in the stability or activity of the phages or
their derived antimicrobial enzymes. In the case of whole phages, this is likely to arise as the result
of broad-spectrum antimicrobial activity which may potentially inactivate the phage along with the
bacterial host [59–61], while in the case of phage-derived antimicrobial enzymes, this could be achieved
through the modification of protein domains as the result of residue oxidation [62]. Therefore, in order
to counteract these potentially harmful effects, it would be necessary to optimize the concentrations
of these compounds in order to minimize the damage that they could cause to the active component
without completely losing any beneficial effects they provide, using standardized test regimes, such as
fractional inhibitory concentration (FIC) or checkerboard testing [63,64].
It is also necessary to consider the solubility of both the adjuncts and the phage/enzymes during the
initial selection process. Unlike antibiotics, whose concentrations, in many cases, can be increased to levels
that are toxic to humans, it is possible that phages will possess an upper threshold of what can be held in
suspension, approximately 1014 PFU/mL for a small phage, such as T7, due to the differences between
their sizes [65]. Such an upper threshold should limit the maximum concentration of each individual
component within a cocktail. The limitation on the upper concentration threshold could result in an overall
decrease in the level of activity. However, commercially available whole phage products can be routinely
produced at titers ≥1010 PFU/mL and are used at concentrations of approximately 109 PFU/mL [66].
If necessary, solubility could theoretically be increased through the addition of solubilizing agents, such
as polysorbate 80, dimethyl sulfoxide (DMSO), or glycerin [67], it should be noted that some solubilizing
agents, such as DMSO, can be antimicrobial at higher concentrations.
Table 2. Requirements for pharmaceutical preparations by application type. G−: Gram-negative [13,68–71].
Route of
Administration
Total Aerobic
Microbial Count
(CFU/g or CFU/mL)
Total Combined
Yeast/Mold Count
(CFU/g or CFU/mL)
Absence of Specific
Microorganisms
cGMP
Requirement
Defined
Endotoxin
Limits
Oral
Non-aqueous 103 102
E. coli Yes NoAqueous 102 101
Buccal/Gingival 102 101 S. aureus
Skin
Transdermal
102 101 S. aureus and P. aeruginosa Yes NoCutaneous
Injectable 0 0 - Yes
Vaginal 102 101
S. aureus and P. aeruginosa and
Candida albicans Yes No
Rectal 103 102 - Yes No
Inhalation 102 101
S. aureus, P. aeruginosa and bile
tolerant G− bacteria Yes No
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3. Increasing Antibacterial Activity and Host Range
Among the key double-edged advantages of therapies (based upon whole phages or their derived
antimicrobial enzymes compared to conventional antibiotics) is that their specific activity minimizes
the collateral damage to commensal microflora at the same time as limiting the host range of each
therapy. When designing whole-phage-based therapies, multiple phages are combined into cocktails,
with the selection of phages with optimal characteristics of key importance. However, it is often
assumed that the best criteria for phage activity are dependent on in vitro properties and independent
of the type of application [57,58,68,72]. This could lead to the exclusion of some phages which may
better suit a particular application. For example, if one was to attempt to reduce the risk of contracting
a particular disease in a cattle herd (prevention therapy), such as mastitis, then a phage cocktail
which possesses a broad host range, greater environmental stability, and longer lasting lytic activity
would prove more useful than a cocktail which targets a limited number of hosts and is susceptible to
environmental conditions. Conversely, for active infections against a single characterized bacterium,
faster-acting phages with large burst sizes would be more useful (intervention therapy). In the sections
below, combinations of phages, their derived antimicrobial enzymes, and additional compounds will
be discussed.
3.1. Phage Cocktails
Perhaps the most routinely used and well-studied form of formulation, phage cocktails are
comprised of multiple phages on the basis of desirable in vitro characteristics (e.g., activity and/or
host range) in order to enhance the host range and potentiate overall activity when compared to the
individual components [73–76]. A summary of in vivo cocktail testing can be found in Table 3. Such
combinations possess significantly more complex dynamics compared to individual phages have been
reviewed in detail elsewhere and are generally shown to increase antibacterial activity compared to
individual phages [76–78]. Although phage cocktails are well studied, there are a number of areas in
which additional research could be focused on (e.g., increasing phage host range, phage pharmacology,
host immune response, etc. [79]), which would provide additional information for the selection of
phages in cocktails.
Some of the complexities of active treatment (interventionist) phage cocktail dynamics involve
the ability of a single phages to outcompete the other phage components of the cocktail via
competition for bacterial binding sites and the loss of phage activity from superinfection exclusion, to
lower-risk outcomes which may include the inability to infect resistant bacteria compared to a single
phage [18,19,76,78]. While competition for binding sites is perhaps the most obvious example of this,
competition could also arise from differences in the replication dynamics of the phage in which one
phage possesses a shorter latent period (the time between infection and bacterial lysis) compared to
other phages in the cocktail. This competition could, thus, decrease the overall efficacy of the treatment
through the faster propagation one of them gets. Indeed, within the published literature, the change in
the titer of individual phage components is often not studied and, instead, relies upon the reporting
of the total phage content [80–82]. Competition between phages for bacterial binding sites could
also potentially have a deleterious effect on phage activities in cocktails where phages are applied
simultaneously (immediate release), in the absence of any other compounds or formulation and, as
such, it would be advantageous to select phages which target different bacterial receptors. Although
there are a number of well-characterized examples of surface receptors for phage binding [83–85], they
are often overlooked when selecting phages.
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Table 3. Summary of non-safety in vivo phage cocktail studies. i.c.: intracavity wash; i.v.: intravenous.
Condition Targeted Bacterial Species Cocktail Composition Results References
Human Chronic otitis P. aeruginosa Biophage PA (six phages; BC-BP-01to BC-BP-06) 105 PFU per phage
• Clinical indicators improved in phage treated patients
compared to placebo
• P. aeruginosa counts significantly lower in phage
treated group compared to placebo
[86]
Human necrotic pancreatitis Acinetobacter baumnnii
Three phage cocktails used; φPC
(i.c.), φIV (5 × 109 PFU i.v.) and
φIVB (5 × 109 PFU i.v.)
• Patient survived and fully recovered
• Resistance to cocktails φPC and φIV after 8 days
• Phage serum concentration dropped to 20 PFU/mL
after 120 min
[87]
Murine Bacteremia Klebsiella pneumoniae GH-K1, GH-K2, GH-K3
• Cocktail reduced bacterial titre approx. 3–4log10
compared to monophage
• Cocktail counts decreased ≤2log10 in 90–120 min
[88]
Necrotic Enteritis of boiler
chickens Clostridium perfringens
C. perfringens phages (CPAS-7,
CPAS-12, CPAS-15, CPAS-16and
CPLV-42) in equal amounts
• Mortality <1% when administered with water or feed.
Compared to 64% in controls [89]
Mouse model of mastitis S. aureus
Twelve phage cocktail (composition
unknown except for two phages;
BP39 and mutant of ATCC 23361)
• Bacterial counts approximately 4–5log10 in mammary
tissue for cocktail treated group compared ≤2log10 for
cefalonium treated control.
[90]
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3.2. Combination with Antibiotics
With the rise of multidrug antibiotic resistance among once-susceptible bacteria, such as
Klebsiella pneumoniae, multiple antibiotics are often combined to produce an effective therapy [91,92].
With combination therapy, the aim is to produce a synergistic or additive effect which eradicates the
infection. Although there are a number of studies which suggest that these antibiotic combinations
could select for mutations, allowing for broad-spectrum resistances which can be passed on to
susceptible bacteria, the data remains contradictory [91,93–96]. As such, the use of phages and
antibiotics in combination could prove to be beneficial, as there is data to suggest that overall
activity of formulations is increased (Table 4) and that the formulation selects against drug-resistant
phenotypes [97–101]. This synergistic potential has also been demonstrated for a number of
endolysin/antibiotic combinations [102,103]. However, the combination of phages and antibiotics
could potentially reduce the overall activity of the phage component in an active treatment, by targeting
phage-infected and non-infected cells alike, and potentially interfere with phage replication.
In one such study by Oechslin and colleagues, a 12-phage cocktail (PP1131 at 108 PFU/mL)
which targeted P. aeruginosa was able to increase the in vitro bacterial kill by over 4log10 over a 24-h
period when combined with 2.5 times the minimum inhibitory concentration (MIC) of ciprofloxacin
(a known inducer of prophages) or meropenem when compared to phage or antibiotic alone. In vivo
studies by the same group showed that the cocktail possessed a half-life of approximately 2.3 h in the
plasma while the half-life was reported as approximately 9 h in other organs and that in animals with
endocarditis, negative cultures (≤2log10 CFU/g) were observed in seven of the 11 animals provided
combination therapy compared to monotherapy groups (≥6log10 CFU/g) [80].
The combination of antibiotics and bacteriophage-derived endolysins has also been shown
to increase antibacterial activity components in Gram-positive bacteria. A study by Becker et al.
demonstrated that there was a strong synergy between the LysK and lysostaphin using a turbidity
reduction assay providing a calculated ΣFIC of 0.45± 0.07 [102]. A synergistic effect was also shown by
Garcia and colleagues who demonstrated that the combination of the Staphylococcal endolysin LysH5
with Nisin was able to induce synergy and increase the antibacterial activity eight-fold against a single
strain of Staphylococcus aureus in a checkerboard MIC assay and pasteurized milk [104]. While this
approach shows promise for Gram-positive pathogens, there is limited knowledge on the combinations
of endolysins and antibiotics against Gram-negative pathogens.
The global consumption of antibiotics has increased between 2000 and 2010 and there are a
number of different strategies for combatting this. The introduction of antibiotic stewardship programs
is one such strategy to reduce consumption in human and veterinary medicine [2,105–107]. Although
such stewardship programs and combinations are shown to possess advantages (increased overall
activity, etc.) combining phages with antibiotics is counterintuitive, if the overall aim of these programs
is to reduce the consumption of antibiotics. Such a move would not necessarily significantly impact the
amount of antibiotics used in combinatorial therapy and the need for broad-spectrum agents would
also not decrease. As such, additional research into combinatorial therapy with other non-antibiotic
agents should be undertaken.
3.3. Combination with Natural Products with Antibacterial Activity
Although much focus has been placed on the combination of phages with antibiotics (both bactericidal
and bacteriostatic), there is little in the way of investigation into the effects of non-antibiotic antibacterial
compounds in combination with phages (Table 5). As with the development of phage therapy, the use of
bulk natural compounds or chemical extracts of these compounds continues to attract interest as alternative
antimicrobial agents as both solo agents and also as antibiotic adjuncts [108,109]. The induction of a
non-phage-based synergistic or additive response represents an alternative way to increase the overall
level of phage therapeutics while potentially simplifying the dynamics of the therapy. However, while
research into combination therapy with antibiotics is ongoing, the synergistic potential of phages with
other non-antibiotic antibacterial adjunct compounds is a currently-understudied area [97–99,110,111].
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Table 4. Examples of phage or derived antimicrobial enzymes and antibiotic combinations. Antibiotic abbreviations based on BSAC where available [112].
Bacterial Target Combination Tested Results References
Phage
P. aeruginosa
Phages σ, σ-1 or 001A/subinhibitory GEN, CIP,
ceftriaxone or polymixin B
• No additive effect in GEN and polymixin B combinations
• Ceftriaxone combinations showed ≥2log10 reduction compared to
individual components by 300 min
[98]
Phage LU27/Streptomycin 120 or 240 µg/mL
• Phage only control showed approx. 1log10 reduction at 70 h
• Bacterial reduction 2–3log10 reduction in 100 µg/mL streptomycin/phage
combination compared to streptomycin only at 70 h
• Delay in antibiotic addition altered pattern of kill
[113]
Burkholderia cepacia Complex Phage KS12/1.25 µg/mL CIP, 5 µg/mL MEM,5.5 µg/mL TET
• Phage/CIP and MEM combinations showed ≥3log10 reduction at 325 min
compared to controls [99]
E. coli Phage φMFP/50 or 20 ng/mL CTX
• Phage titer increased by approx. 1log10 by 120 min post administration
• Plaque sizes increased compared to control [114]
K. pnuemoniae Phage B5055/CIP
• Reduction of bacterial biofilm content of approx. 5log10 180 min after
phage addition
• No significant difference in reduction between combination and phage
only treated biofilms
• Frequency of resistant variants decreased in combined testing compared to
individual components
[115]
S. aureus Phage MR-10/5 mg/Kg MUP
• Phage/MUP combination showed >1log10 reduction in bacterial content by
day 3 post treatment in BALB/c mice compared to controls
• Clearance in Phage/MUP combination by day 5
• Individual components showed clearance by day 10
[116]
Derived
antimicrobial
enzymes
Streptococcus pneumoniae Endolysin Cpl-1/GEN or PEN • Synergy with PEN or GEN was dependent on level of PEN resistance [117]
A. baumannii
Endolyin LysABP-01 (concentrations ranged from
0.0156-2 × MIC)/CIP, IMP, COL, CHLO, GEN, ERY, or
TET (concentrations ranged from 0.0625-2 × MIC)
• Phage/COL showed elevated antibacterial activity (close to 100%) in
comparison to other phage/antibiotic combination [118]
Listeria monocytogenes Endolysin PlyP100/nisin
• Endolysin stable for up to 28 days under cold storage
• PlyP100/nisin combination maintained activity over 4 weeks [119]
S. aureus CF-301/ DAP, VAN
• Synergy between CF-301 and DAP/VAN resulted in increased murine
survival compared to when just treated with antibiotics alone (p < 0.0001) [103]
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Table 5. Examples of phages or derived antimicrobial enzymes in combination non-antibiotic compounds.
Bacterial Target Combination Results References
Phage
K. pneumoniae Phage KPO1K2 or NDP/CoSO4 or FeCl3
• Reduction of ≤1log10 in NDP/10 µM FeCl3 combination in biofilms up to seven
days versus untreated control
• Reduction of 1–2log10 in KPO1K2/10 µM FeCl3 combination in biofilms up to
seven days versus untreated control
• Reduction of ≥5log10 in KPO1K2/10 µM FeCl3 + 500 µM CoSO4 combination in
three day old biofilms versus untreated control
[120]
E. coli O157:H7 Phage cocktail BEC8 (10
6 PFU/leaf)/0.5%
v/v trans-cinnameldehyde
• Total kill (4–6log10 reduction) within 10 min when combined at all conditions
• Individual treatment results varied based on bacterial inoculum and
incubation temperature
[121]
L. monocytogenes Listex P100/potassium lactate andsodium diacetate
• Prevented L. monocytogenes outgrowth for up to28 days compared to controls
• Smaller reduction in bacterial count seen at lower temperatures [122]
Derived
antimicrobial
enzymes
S. aureus Endolysin LysSA97 (376 nM)/carvacrol(3.33 mM)
• Individual components showed reduction in bacterial content of approx. 1log10
• Combination reduced bacterial content >4log10
• Combined activity varied depending on lipid content
[123]
L. monocytogenes
Endolysin PlyP825/High hydrostatic
pressure (HHP)
• Synergistic inactivation of L. monocytogenes in milk, cheese, and smoked fish
• Allows for lower pressure level to be used with the same antimicrobial efficacy
when treated in combination with phage
• Decrease bacteria positive food samples during storage
[124]
Endolysin PlyP40, Ply511 or
PlyP825/High pressure
• Individual treatment reduced bacterial number ≤1log10
• Combined treatment reduced bacterial number ≥5log10 [125]
Various Endolysin Lys68/weak acids
• Lys68/EDTA combination only lysed Pseudomonas
• Lys68/citric or malic acid effected 9 or 11 species, respectively
• Bacterial reduction <3log10 for all conditions tested
[126]
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As with phages, honey has a long history as an antimicrobial agent and has been shown to target
multiple bacterial pathogens, inhibit biofilm formation, and may increase wound healing [127–131].
The broad antimicrobial properties of honey stem from the presence of hydrogen peroxide [132], a
high sugar content, and the presence of methylglyoxal (MGO) and the antimicrobial peptide bee
defensin-1 [133]. However, it should also be noted that the composition of antimicrobial agents
between honeys differs dramatically even within localized areas [134,135]. A recent study by Oliveira
and colleagues has also shown that phages in combination with one of two Portuguese honeys were
able to increase the bactericidal effect against Escherichia coli biofilms over a 24 h period compared to
the phage or alone. However, this increase in antibacterial activity was coupled with a reduction in
phage titer of at least 1log10 within 60 min compared to the inoculum at the lowest concentration of
honey tested [60]. This broad-spectrum antimicrobial activity is undoubtedly useful, but would present
a potential hazard if trying to combine honey with endolysins as both MGO and hydrogen peroxide
act against protein structures via cross-linkage or hydroxyl radical formulation, respectively [136].
The risk of broad spectrum antimicrobial activity when combined with bulk antimicrobial plant
extracts is also seen in Pimchan et al [59]. This study compared the antibacterial effects of three different
bulk plant extracts from plants with known antibacterial properties in combination with two different
E. coli phages. As the plant extracts were diluted to reduce the potential adverse effects on the viability
of the phages, a loss of phage titer of approximately 1log10 was only observed for one of the conditions
tested. However, this also reduced the overall antibacterial activity compared to the phage alone [59].
Volatile essential oils, such as thymol and carvacrol, extracted from plant materials have also
been previously shown to possess potent antimicrobial properties [137,138]. A study by Ghosh et
al. evaluated the antibacterial properties of Staphylococcal Phage K and a number of essential oil
compounds on the in vitro growth of S. aureus. While both essential oils tested individually were
able to significantly reduce the growth of multiple strains of S. aureus at 37 ◦C, when combined,
the effect was not greatly changed [139]. In contrast to this, Chang and colleagues demonstrated
synergy between carvacrol and the LysSA97 endolysin in milk with individual components producing
approximately a 1log10 reduction in bacterial content while the combination reduced bacterial content
by approximately 4.5log10. This study also suggested that an increased lipid content decreased the
synergistic activity [123].
While the combination of natural products and bacteriophages appears to exhibit some promise,
extra attention should be paid to the characterization of active components within bulk compounds.
Such an approach could potentially yield compounds with potent and specific antibacterial properties.
In addition, determining the mechanism of action of such compounds would also be of use. In
particular, the selection of compounds which do not interfere with protein structure would be
advantageous for both whole phage and phage-derived antimicrobial enzymes.
3.4. Combination with Non-Antibacterial Compounds
Although the combination of additional antibacterial agents with phages or their derived
antimicrobial enzymes could increase the overall activity of formulations and would be advantageous
in intervention therapies, it only enhances a single aspect, the overall kill, and only targets vegetative
bacterial species. For preventative measures the overall level of bacterial kill is less important and the
ability of the phage to infect its bacterial host becomes more important. As such, the enhancement of the
binding and adsorption efficacy of the phage or phage-derived antimicrobial enzyme (e.g., endolysins)
could also increase the efficacy of preventative treatments.
The presence of divalent ions (particularly Ca2+ ions) is well known to play a role in enhancing
the binding efficacy of phages and many phage buffers consequently are supplemented with Ca2+ ions
(Table 5) [120,140–142]. A study by Bandara and colleagues showed that Ca2+, Mg2+ or Mn2+ ions were
required to allow Bacillus Phages BCP1-1 and BCP8-2 to infect Bacillus cereus strains in a fermented
soybean paste [143]. A study by Garcia and colleagues combined the Staphylococcal endolysin LysH5
with nisin, in the presence of metal ions. They concluded that LysH5 activity was enhanced in the
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presence of Ca2+, Mg2+ and NaCl but inhibited by Mn2+ and Zn2+ [104]. Therefore, the inclusion of ion
chelators, such as ethylenediaminetetraacetic acid (EDTA), as excipients could potentially decrease the
efficacy of phage or endolysin binding, while an ionic solvent with increased Ca2+ ion concentration
could potentially increase the overall level of phage binding [67,144].
3.5. Formulation Against Spores and Biofilms
When presented with unfavorable conditions, such as depleted nutrient sources, and the presence
of antimicrobials, some bacterial species have developed strategies to enable them to persist in the
environment. These include the ability to form bacterial endospores as is the case with Bacillus and
Clostridia species and the ability to produce bacterial biofilms which are considered more resistant to
antibiotic and chemical decontamination treatments compared to their vegetative counterparts [145,146].
Phages and endolysins from these two bacterial species have been reviewed elsewhere in more detail [147].
Bacterial spores could be targeted with germinant compounds in order to convert the
potentially-resistant spore form into the susceptible vegetative state [148], while extracellular
capsules which prevent phage infections could be degraded through the addition of recombinant
enzymes [17,149], although there is some suggestion that endolysins may be capable of interacting
with the endospore [150]. However, it is important to note that the induction of spore germination
in human therapeutics would be highly dangerous and unethical, but for non-clinical applications
(particularly wide-area decontamination), the induction of spore germination has resulted in enhanced
bacterial destruction [146,151]. The type of germinant that would be required would vary between
bacterial species, with bile salts commonly used for Clostridia species and a combination of L-alanine
and inosine effective in Bacillus [148,152–154]. However, additional research into the efficacy and
interactions between phages or phage derived antimicrobial enzymes is still required.
Bacterial biofilms represent a serious healthcare issue accounting for up to 80% of all microbial
infections and are often prevalent in a number of chronic conditions. Such conditions, including
cystic fibrosis lung infections and chronic burns, are often poly-microbial in nature [155–157]. In these
conditions, the biofilm acts in a variety of different ways which can result in the failure of antibiotic
treatment [158]. Biofilms can act as a permeability barrier to both antibiotics and antimicrobial metals, as
well as to non-specific immune mechanisms [159–162]. While phages are capable of reaching bacteria
within biofilms, the production of exopolymeric substances (EPS) can act as a non-specific barrier
to phages, reducing the amount that are able to infect susceptible cells. In response to this, some
phages possess EPS de-polymerases which can disrupt biofilms (Table 6). Although these enzymes
are not directly antimicrobial, they could potentially increase the amount of phages that can reach
bacterial targets by degrading EPS, while disrupting the overall biofilm structure and exposing persister
cells [163–165]. The development of phage derived EPS de-polymerases may initially be more inefficient
due to the costs associated with research and regulatory approval and the use of traditional approved
mucolytic agents such as ambroxol or acetylcysteine may prove more financially viable [166,167].
Table 6. Examples of bacteriophage-derived depolymerase enzymes.
Bacterial Target Phage Summary Reference
A. baumannii
Petty Enzymatic activity from Dpo1 depolymerase protein from Petty degradedpurified EPS from A. baumannii [168]
ϕAB6 ϕAB6 has a polysaccharide depolymerase degraded A. baumannii EPS andis a component of the phage tail fiber that determines host specificity [169]
E. coli
VB_EcoM_ECOO78 Dpo42 prevented biofilm formation in 15 clinical E. coli strains and reducedbiofilm formation when compared to negative controls [170]
K1, K5, and K30
• Addition of polymerase increased mouse survival at five days post
bacterial exposure in a concentration dependent manner
• Differences in survival were observed between different
depolymerase types
• Depolymerase in combination with serum enhanced bacterial killing
compared to controls
[171]
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Table 6. Cont.
Bacterial Target Phage Summary Reference
Klebsiella
ϕK64-1
Phage encoded 8 putative depolymerases
Production of phage mutants that did not encode putative depolymerases
eliminated lytic activity
[172]
K5-2 and K5-4
• Each phage encodes for two different capsule depolymerases that
allows them to replicate on certain Klebsiella strains
• K5-2 causes spots on seven capsular types of Klebsiella
• K5-4 increased survival of mice treated with K. pneumoniae K5 strain
[173]
KP32
Tail tubular protein A (TTPA), a structural tail protein of KP32, exhibits
lytic activity towards EPS. TTPA can be regarded as a dual function
macromolecule with both structural and enzymatic activities
[174]
Erwinia amylovora L1 DpoL1 is required for L1 uptake and specifically binds to, and degrades, E.amylovora EPS by cleaving the amylovoran galactose backbone [175]
Table 7. Examples of modified-release dosage of phages or phage-derived antimicrobial enzymes.
HPMC: Hydroxypropylmethylcellulose; PNIPAM: Poly (N-isopropylacrylamide).
Bacterial Target Formulation Results References
Phage
K. pneumoniae Phage Kpn5/HPMChydrogel
• Enhanced survival (≥60%) of burnt mice over
five days [176]
S. aureus Phage K/alginatemicrospheres
• Encapsulation significantly improved survival in
simulated gastric fluid
• Incorporation of trehalose, sucrose, skimmed milk,
or maltodextrin-improved phage viability
following drying
[177]
Salmonella
Enteritidis
Phage f3αSE/ alginate
spheres
• Encapsulation extended phage release to over
200 h compared to control [178]
Propionibacterium
acnes
Phages
PAC1-10/cetomacrogol
cream
• Phage activity maintained over 90 days when
preparation maintained at 4 ◦C in the dark [51]
C. difficilie Phage CDKM9/Eudragit ±alginate
• Encapsulated phage withstood simulated gastric
fluid for 3 h
• Release triggered at pH 7
[179]
Derived
antimicrobial
enzymes
S. aureus
Endolysin CHAPk and
lysotaphin in PNIPAM
nanoparticles
• Both enzymes work synergistically to lyse S. aureus
with a fast response time in comparison to choice
antibiotic used for MRSA treatment
• PNIPAM allowed for successful diffusion while
maintain stability of the enzybiotic cocktail
[180]
4. Enhancing Storage, Dosing, and Delivery
Any final formulation involving whole phages, phage-derived antimicrobial enzymes, and adjunct
components will have to consider the intended application. How such therapeutics are stored and
delivered could influence the potential shelf life, persistence in vivo, and the overall efficacy of the
phage and non-phage adjuncts [13,181,182]. Although clinical and non-clinical applications share
some of the same requirements for storage and delivery (e.g., long shelf life at ambient temperatures),
which would enable research to be carried out more effectively, it is likely that each treatment area will
possess unique requirements.
The susceptibility of whole phages to environmental stresses (pH, temperature, humidity, etc.)
can be highly variable under non-formulated conditions, although most can tolerate relatively wide
pH and temperature ranges [14,126,183–186]. These varying degrees of susceptibility will have an
important impact, not only during manufacturing, formulation, and routine storage, but also during
therapeutic applications, particularly when encountering a hostile environment (e.g., transiting the
stomach) [186]. In order to increase the long-term storage of phages, they have been lyophilized in
the presence of different sugars for increased stability and allowing delivery in a powdered form,
e.g., in metered-dose inhalers [187–189]. Additionally, phages or their derived antimicrobial enzymes
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could be formulated into liquid formulations, but in order to maintain pharmacopeia compliance,
preservatives or other compounds may be required to prevent microbial contamination.
As discussed earlier, the overall efficacy of a phage cocktail could be compromised (assuming
an immediate application of all phages) as one phage reproduces more efficiently than the other
components (e.g., more efficient adsorption and shorter latency period) or as phages compete for
binding sites when applied simultaneously. This competition could be reduced by the selection of
phages which do not compete with one another in cocktails or applying individual phages at different
times initially, as there are also solutions through formulation which could enhance and simplify this
process. Modified release dosage allows for drug delivery with a delay from the time of administration
or prolonged release and is used for pain management [190–192]. Simple liquid suspensions are
most commonly used for topical and oral applications [193–196]. While these suspensions are able
to effectively rinse infected wounds as large volumes of suspension can be applied, much of the
suspension is lost as it runs off the site of infection. However, for applications which require a surface
contact (e.g., food preservation and wound infections), impregnated materials, such as hydrogels
(Table 7), are increasingly being researched as these would allow for a constant release of phage or
antimicrobial enzyme by maintaining contact with the contaminated area. This could ultimately result
in less wastage, but optimization would be required to ensure that an effective dose is delivered.
Encapsulating the phage or derived antimicrobial enzyme within polymer microparticles
(Table 7) [177] could also prove beneficial. By encapsulation of biofilm-disrupting compounds, such as
ambroxol, which are released prior to the release of the phage, the overall efficacy could be enhanced
as they would enable greater penetration into the biofilm layer. Such polymer microparticles have
been shown to be able to be triggered into releasing their “drug” components through a variety of
triggers, including pH and temperature, each of which would benefit specific applications (e.g., low
temperature release for food preservation and low pH to survive transit through the gastrointestinal
tract) [179,180]. Encapsulation of formulations within microfluidic-produced microcapsules would
also allow for the production of uniformly-sized particles [179,197], which for inhalational use would
mean that specific areas of the lung could be targeted [198]. While for larger scale spray applications
(e.g., crop protection), uniformly-sized particles in combination with effective delivery technology
could optimize surface coverage [199].
5. Phage Degradation and Immunogenicity
There is evidence to suggest that the release of bacterial endotoxins (in particular
lipopolysaccharide; LPS) does not increase and that the overall outcome of phage therapy is not
compromised due to anti-phage immune responses in phage-treated complex systems [20,137,200–202].
There are still areas in which further research is necessary, as the level and type of immune response
encountered is likely to change depending on the therapy approach. For example as an additive
to animal feed, where phages would be given over long periods of time, this could result in the
development of phage-specific antibodies [35,203]. While the incorporation of immunomodulatory
compounds into therapies could be potentially ethically and practically inadvisable, there are a
number of anti-LPS compounds (such as lipoamines or some alkaloids) that have been shown to
reduce pro-inflammatory responses caused by LPS [204–207]. However, these would need to be tested
to determine their ability to work in synergy with phages or their derived antimicrobial enzymes.
An alternative approach would be to mask phages or antimicrobial enzymes from the immune
system. Such an approach has been described by Kim et al. This approach involved the pegylation
of whole phages and suggest that phage half-life in a mice was increased and exhibited significantly
lower levels of IFN-γ and IL-6 release [208,209]. However in the case of endolysins, a later study
by Resch et al. showed that the pegylation of a Streptococcus pneumoniae specific endolysin (Cpl-1)
exhibited significantly lower activity than that of the native enzyme [210].
Within reported human cases within Western hospitals, dosing requirements are often based on
the endotoxin content of a phage preparation rather than the phage content in order to maximize
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the amount of phages that can be delivered during a single treatment while meeting regulatory
requirements [87,202]. It should be noted that some phage clinical trials have provided little
information about the overall dosing and concentration of the active phage component [211]. While
such studies have shown promise, there is still limited knowledge surrounding the dosing requirements
for phages and phage-derived antimicrobial enzymes when applied in vivo as antibiotic alternatives.
6. Concluding Remarks
Therapeutics based on whole phages (or their derived antimicrobial proteins) represent an exciting
alternative to conventional antibacterial treatments in both clinical and non-clinical scenarios. While
for human clinical applications, there are a number of clinical successes reportedly supported by
growing in vitro testing and in vivo testing which suggests that whole-phage therapy is viable for a
variety of conditions. However, it is important to note that these reported human cases are often
on a limited number of patients and have been based on compassionate or magisterial phage usage
rather than taking the form of regulated clinical trials [15,212,213]. In non-clinical applications, whole
phages and endolysins have found some commercial success as food additives to prevent bacterial
contamination (Table 1), but phage-based medicines have yet to successfully navigate the clinical
approvals process. For whole phages this partly stems from an incompatibility with regulatory
processes and the potential need for phage-specific approval pathways. It also reflects a need for
increased collaboration between regulators and developers to decide what form phage therapy should
take (bespoke or pre-manufactured), the desired outcome of any treatment (prevention or intervention)
and the type of regulation that is necessary for widespread implementation (full regulatory approval
or compassionate usage only) as for each area different selection criteria could be required.
Currently available commercial products or compassionately-used therapies often contain simple
cocktails of phages or phage-derived antimicrobial enzymes (e.g., endolysins) that are, in the majority
of cases, applied directly to target areas and contain few, if any, additional components. Indeed,
while the development of more complex pharmaceuticals with phages or phage-derived antimicrobial
enzymes as their main active ingredients may allow for some of the limitations to be addressed, this is
currently understudied. However, it would be necessary to study the pharmacology and secondary
effects of such combinations in vitro.
It is unlikely that whole-phage products will become the widespread antibiotic alternative that
they are considered to be by some. While the implementation of complex formulations may help
to address some of the biologically-imposed limitations of whole-phage treatments, these will come
with additional financial costs and also further complicate the already complex nature of phage
pharmacology. While the information presented in the current review is not an exhaustive comparison,
it is important to note that any complete formulation will likely be the result of tradeoffs designed to
maximize benefits and minimize deficiencies.
Acknowledgments: This work was supported by the Olle Engkvist Byggmästare Foundation under grant number
2015/419; and the Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning
(FORMAS) coordinated by the Animal Health and Welfare (ANIHWA) project within the European Research Area
(ERA-NET) under grant number 221-2015-1894.
Author Contributions: All authors contributed equally to the manuscript.
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Van Boeckel, T.P.; Gandra, S.; Ashok, A.; Caudron, Q.; Grenfell, B.T.; Levin, S.A.; Laxminarayan, R. Global
antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data. Lancet Infect. Dis.
2014, 14, 742–750. [CrossRef]
2. Van Boeckel, T.P.; Brower, C.; Gilbert, M.; Grenfell, B.T.; Levin, S.A.; Robinson, T.P.; Teillant, A.;
Laxminarayan, R. Global trends in antimicrobial use in food animals. Proc. Natl. Acad. Sci. USA 2015, 112,
5649–5654. [CrossRef] [PubMed]
Pharmaceuticals 2018, 11, 34 15 of 25
3. Webber, M.A.; Whitehead, R.N.; Mount, M.; Loman, N.J.; Pallen, M.J.; Piddock, L.J.V. Parallel evolutionary
pathways to antibiotic resistance selected by biocide exposure. J. Antimicrob. Chemother. 2015, 70, 2241–2248.
[CrossRef] [PubMed]
4. Soumet, C.; Méheust, D.; Pissavin, C.; Le Grandois, P.; Frémaux, B.; Feurer, C.; Le Roux, A.; Denis, M.; Maris, P.
Reduced susceptibilities to biocides and resistance to antibiotics in food-associated bacteria following
exposure to quaternary ammonium compounds. J. Appl. Microbiol. 2016, 121, 1275–1281. [CrossRef]
[PubMed]
5. Ng, K.M.; Ferreyra, J.A.; Higginbottom, S.K.; Lynch, J.B.; Kashyap, P.C.; Gopinath, S.; Naidu, N.;
Choudhury, B.; Weimer, B.C.; Monack, D.M.; et al. Microbiota-liberated host sugars facilitate post-antibiotic
expansion of enteric pathogens. Nature 2013, 502, 96–99. [CrossRef] [PubMed]
6. Faber, F.; Tran, L.; Byndloss, M.X.; Lopez, C.A.; Velazquez, E.M.; Kerrinnes, T.; Nuccio, S.-P.; Wangdi, T.;
Fiehn, O.; Tsolis, R.M.; et al. Host-mediated sugar oxidation promotes post-antibiotic pathogen expansion.
Nature 2016, 534, 697–699. [CrossRef] [PubMed]
7. Meader, E.; Mayer, M.J.; Steverding, D.; Carding, S.R.; Narbad, A. Evaluation of bacteriophage therapy to
control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe 2013, 22,
25–30. [CrossRef] [PubMed]
8. Wang, J.; Gao, Y.; Zhao, F. Phage-bacteria interaction network in human oral microbiome. Environ. Microbiol.
2016, 18, 2143–2158. [CrossRef] [PubMed]
9. Zhao, J.; Liu, Y.; Xiao, C.; He, S.; Yao, H.; Bao, G. Efficacy of Phage Therapy in Controlling Rabbit Colibacillosis
and Changes in Cecal Microbiota. Front. Microbiol. 2017, 8. [CrossRef] [PubMed]
10. Abedon, S.T.; Kuhl, S.J.; Blasdel, B.G.; Kutter, E.M. Phage treatment of human infections. Bacteriophage 2011,
1, 66–85. [CrossRef] [PubMed]
11. Viertel, T.M.; Ritter, K.; Horz, H.-P. Viruses versus bacteria—Novel approaches to phage therapy as a tool
against multidrug-resistant pathogens. J. Antimicrob. Chemother. 2014, 69, 2326–2336. [CrossRef] [PubMed]
12. Sulakvelidze, A. Using lytic bacteriophages to eliminate or significantly reduce contamination of food by
foodborne bacterial pathogens. J. Sci. Food Agric. 2013, 93, 3137–3146. [CrossRef] [PubMed]
13. Cooper, C.J.; Khan Mirzaei, M.; Nilsson, A.S. Adapting Drug Approval Pathways for Bacteriophage-Based
Therapeutics. Front. Microbiol. 2016, 7, 1209. [CrossRef] [PubMed]
14. Cooper, I.R. A review of current methods using bacteriophages in live animals, food and animal products
intended for human consumption. J. Microbiol. Methods 2016, 130, 38–47. [CrossRef] [PubMed]
15. Totté, J.E.E.; van Doorn, M.B.; Pasmans, S.G.M.A. Successful Treatment of Chronic Staphylococcus aureus-Related
Dermatoses with the Topical Endolysin Staphefekt SA.100: A Report of 3 Cases. Case Rep. Dermatol. 2017, 9,
19–25. [CrossRef] [PubMed]
16. Bryan, D.; El-Shibiny, A.; Hobbs, Z.; Porter, J.; Kutter, E.M. Bacteriophage T4 Infection of Stationary Phase
E. coli: Life after Log from a Phage Perspective. Front. Microbiol. 2016, 7. [CrossRef] [PubMed]
17. Negus, D.; Burton, J.; Sweed, A.; Gryko, R.; Taylor, P.W. Poly-γ-D-Glutamic Acid Capsule Interferes with
Lytic Infection of Bacillus anthracis by B. anthracis-Specific Bacteriophages. Appl. Environ. Microbiol. 2013, 79,
714–717. [CrossRef] [PubMed]
18. Barrangou, R.; van der Oost, J. Bacteriophage exclusion, a new defense system. EMBO J. 2015, 34, 134–135.
[CrossRef] [PubMed]
19. Barrangou, R. The roles of CRISPR-Cas systems in adaptive immunity and beyond. Curr. Opin. Immunol.
2015, 32, 36–41. [CrossRef] [PubMed]
20. Górski, A.; Mie˛dzybrodzki, R.; Borysowski, J.; Da˛browska, K.; Wierzbicki, P.; Ohams, M.; Korczak-Kowalska, G.;
Olszowska-Zaremba, N.; Łusiak-Szelachowska, M.; Kłak, M.; et al. Phage as a Modulator of Immune Responses:
Practical Implications for Phage Therapy. In Advances in Virus Research; Bacteriophages, Part B; Łobocka, M.,
Szybalski, W., Eds.; Elsevier Science Publishing: Amsterdam, The Netherlands, 2012; Chapter 2, Volume 83,
pp. 41–71.
21. Łusiak-Szelachowska, M.; Zaczek, M.; Weber-Da˛browska, B.; Mie˛dzybrodzki, R.; Kłak, M.; Fortuna, W.;
Letkiewicz, S.; Rogóz˙, P.; Szufnarowski, K.; Jon´czyk-Matysiak, E.; et al. Phage neutralization by sera of
patients receiving phage therapy. Viral Immunol. 2014, 27, 295–304. [CrossRef] [PubMed]
22. Nguyen, K.; Simmons, K.; Tatarnikov, I. Co-inoculation of Escherichia coli B23 by T4 and T7 bacteriophages
results in competition shown by an overall drop in phage progeny. J. Exp. Microbiol. Immunol. 2014, 18,
156–161.
Pharmaceuticals 2018, 11, 34 16 of 25
23. Bremner, W.; Campbell, T.; Ferera, J.; Zaman, R. Evaluating Double Agar Overlay Assay and Flow Cytometry
as Methods for Characterizing Competition between T4 and T7 Bacteriophages in Escherichia coli C600. J. Exp.
Microbiol. Immunol. 2016, 20, 69–77.
24. Roach, D.R.; Donovan, D.M. Antimicrobial bacteriophage-derived proteins and therapeutic applications.
Bacteriophage 2015, 5. [CrossRef] [PubMed]
25. Endersen, L.; Guinane, C.M.; Johnston, C.; Neve, H.; Coffey, A.; Ross, R.P.; McAuliffe, O.; O’Mahony, J.
Genome analysis of Cronobacter phage vB_CsaP_Ss1 reveals an endolysin with potential for biocontrol of
Gram-negative bacterial pathogens. J. Gen. Virol. 2015, 96, 463–477. [CrossRef] [PubMed]
26. Linden, S.B.; Zhang, H.; Heselpoth, R.D.; Shen, Y.; Schmelcher, M.; Eichenseher, F.; Nelson, D.C. Biochemical
and biophysical characterization of PlyGRCS, a bacteriophage endolysin active against methicillin-resistant
Staphylococcus aureus. Appl. Microbiol. Biotechnol. 2015, 99, 741–752. [CrossRef] [PubMed]
27. Oliveira, H.; Vilas Boas, D.; Mesnage, S.; Kluskens, L.D.; Lavigne, R.; Sillankorva, S.; Secundo, F.;
Azeredo, J. Structural and Enzymatic Characterization of ABgp46, a Novel Phage Endolysin with Broad
Anti-Gram-Negative Bacterial Activity. Front. Microbiol. 2016, 7. [CrossRef] [PubMed]
28. Maciejewska, B.; Olszak, T.; Drulis-Kawa, Z. Applications of bacteriophages versus phage enzymes to combat
and cure bacterial infections: An ambitious and also a realistic application? Appl. Microbiol. Biotechnol. 2018,
102, 2563–2581. [CrossRef] [PubMed]
29. Briers, Y.; Lavigne, R. Breaking barriers: Expansion of the use of endolysins as novel antibacterials against
Gram-negative bacteria. Future Microbiol. 2015, 10, 377–390. [CrossRef] [PubMed]
30. Rodríguez-Rubio, L.; Gutiérrez, D.; Donovan, D.M.; Martínez, B.; Rodríguez, A.; García, P. Phage lytic
proteins: Biotechnological applications beyond clinical antimicrobials. Crit. Rev. Biotechnol. 2016, 36, 542–552.
[CrossRef] [PubMed]
31. Song, J.; Xia, F.; Jiang, H.; Li, X.; Hu, L.; Gong, P.; Lei, L.; Feng, X.; Sun, C.; Gu, J.; et al. Identification and
characterization of HolGH15: The holin of Staphylococcus aureus bacteriophage GH15. J. Gen. Virol. 2016, 97,
1272–1281. [CrossRef] [PubMed]
32. Zhang, W.Y. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Saf. 2001, 24, 1127–1142.
[CrossRef] [PubMed]
33. Elder, D.P.; Kuentz, M.; Holm, R. Pharmaceutical excipients—Quality, regulatory and biopharmaceutical
considerations. Eur. J. Pharm. Sci. 2016, 87, 88–99. [CrossRef] [PubMed]
34. Pasquet, J.; Chevalier, Y.; Couval, E.; Bouvier, D.; Bolzinger, M.-A. Zinc oxide as a new antimicrobial
preservative of topical products: Interactions with common formulation ingredients. Int. J. Pharm. 2015, 479,
88–95. [CrossRef] [PubMed]
35. Garcia-Fernandez, M.J.; Tabary, N.; Chai, F.; Cazaux, F.; Blanchemain, N.; Flament, M.-P.; Martel, B. New
multifunctional pharmaceutical excipient in tablet formulation based on citric acid-cyclodextrin polymer.
Int. J. Pharm. 2016, 511, 913–920. [CrossRef] [PubMed]
36. Basavaraj, S.; Betageri, G.V. Can formulation and drug delivery reduce attrition during drug discovery and
development—Review of feasibility, benefits and challenges. Acta Pharm. Sin. B 2014, 4, 3–17. [CrossRef]
[PubMed]
37. Intralytix, Inc. ListShieldTM. Available online: http://www.intralytix.com/files/prod/01LP/01LP-Desc.pdf
(accessed on 16 March 2018).
38. Intralytix, Inc. EcoShieldTM. Available online: http://www.intralytix.com/files/prod/07EP/07EP-Desc.pdf
(accessed on 16 March 2018).
39. Intralytix, Inc. SalmoFreshTM. Available online: http://www.intralytix.com/files/prod/02SP/02SP-Desc.
pdf (accessed on 16 March 2018).
40. Intralytix, Inc. ShigaShieldTM. Available online: http://www.intralytix.com/index.php?page=prod&id=8
(accessed on 16 March 2018).
41. Product Info – AgriPhageTM. Available online: https://www.agriphage.com/product-info/ (accessed on 20
March 2018).
42. Phagoburn: Evaluation of phage therapy for the treatment of burn wound infections. Available online:
http://www.phagoburn.eu/ (accessed on 20 March 2018).
43. ClinicalTrials.gov. Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas
Aeruginosa Wound Infections in Burned Patients. Available online: https://clinicaltrials.gov/ct2/show/
NCT02116010 (accessed on 19 December 2017).
Pharmaceuticals 2018, 11, 34 17 of 25
44. PneumoPhage: A Collaborative Research Project for the Development of an Effective Phage Therapy
Treatment against Respiratory Tract Infections. Available online: http://www.pherecydes-pharma.com/
pneumophage.html (accessed on 20 March 2018).
45. PHOSA: A Collaborative Research Project for the Development of an Innovative Phage Therapy Treatment
against Bone/Joint and Diabetic foot Ulcer Infections. Available online: http://www.pherecydes-pharma.
com/phosa-collaborative-project.html (accessed on 20 March 2018).
46. AmpliPhi Bioscineces Company: Pipeline. Available online: http://www.ampliphibio.com/pipeline/
(accessed on 20 March 2018).
47. StaphefektTM Technology. Available online: https://www.staphefekt.com/en/content/technology
(accessed on 20 March 2018).
48. ClinicalTrials.gov. The Effect of Gladskin on Disease Severity and the Skin Microbiome, Including
Staphylococcus Aureus, in Patients with Atopic Dermatitis. Available online: https://clinicaltrials.gov/ct2/
show/NCT02840955 (accessed on 20 March 2018).
49. CF-301: ContraFect Corporation (CFRX). Available online: https://www.contrafect.com/pipeline/cf-301
(accessed on 20 March 2018).
50. World Health Organization. Guidelines on the Nonclinical Evaluation of Vaccine Adjuvants and Adjuvanted
Vaccines; World Health Organization: Geneva, Switzerland, 2013.
51. Brown, D.F.J.; Wootton, M.; Howe, R.A. Antimicrobial susceptibility testing breakpoints and methods from
BSAC to EUCAST. J. Antimicrob. Chemother. 2016, 71, 3–5. [CrossRef] [PubMed]
52. Jorgensen, J.H.; Turnidge, J.D. Susceptibility Test Methods: Dilution and Disk Diffusion Methods. In Manual
of Clinical Microbiology, 11th ed.; American Society of Microbiology: Washington, DC, USA, 2015;
pp. 1253–1273. [CrossRef]
53. Carlson, K. Working with bacteriophages: Common techniques and methodological approaches.
In Bacteriophages: Biology and Applications; Kutter, E., Sulakvelidze, A., Eds.; CRC Press: Boca Raton, FL, USA,
2005; ISBN 978-0-8493-1336-3.
54. Hyman, P.; Abedon, S.T. Practical Methods for Determining Phage Growth Parameters. In Bacteriophages; Methods
in Molecular Biology™; Humana Press: New York, NY, USA, 2009; pp. 175–202, ISBN 978-1-58829-682-5.
55. Kutter, E. Phage Host Range and Efficiency of Plating. In Bacteriophages; Methods in Molecular Biology™;
Humana Press: New York, NY, USA, 2009; pp. 141–149, ISBN 978-1-58829-682-5.
56. Mirzaei, M.K.; Nilsson, A.S. Isolation of Phages for Phage Therapy: A Comparison of Spot Tests and
Efficiency of Plating Analyses for Determination of Host Range and Efficacy. PLoS ONE 2015, 10, e0118557.
[CrossRef] [PubMed]
57. Gill, J.J.; Hyman, P. Phage choice, isolation, and preparation for phage therapy. Curr. Pharm. Biotechnol. 2010,
11, 2–14. [CrossRef] [PubMed]
58. Weber-Da˛browska, B.; Jon´czyk-Matysiak, E.; Z˙aczek, M.; Łobocka, M.; Łusiak-Szelachowska, M.; Górski, A.
Bacteriophage Procurement for Therapeutic Purposes. Front. Microbiol. 2016, 7. [CrossRef] [PubMed]
59. Pimchan, T.; Cooper, C.J.; Eumkeb, G.; Nilsson, A.S. In vitro activity of a combination of bacteriophages and
antimicrobial plant extracts. Lett. Appl. Microbiol. 2018, 66, 182–187. [CrossRef] [PubMed]
60. Oliveira, A.; Ribeiro, H.G.; Silva, A.C.; Silva, M.D.; Sousa, J.C.; Rodrigues, C.F.; Melo, L.D.R.; Henriques, A.F.;
Sillankorva, S. Synergistic Antimicrobial Interaction between Honey and Phage against Escherichia coli
Biofilms. Front. Microbiol. 2017, 8. [CrossRef] [PubMed]
61. Gyotoku, T.; Aurelian, L.; Neurath, A.R. Cellulose acetate phthalate (CAP): An “inactive” pharmaceutical
excipient with antiviral activity in the mouse model of genital herpesvirus infection. Antivir. Chem. Chemother.
1999, 10, 327–332. [CrossRef] [PubMed]
62. Heselpoth, R.D.; Owens, J.M.; Nelson, D.C. Quantitative analysis of the thermal stability of the gamma
phage endolysin PlyG: A biophysical and kinetic approach to assaying therapeutic potential. Virology 2015,
477, 125–132. [CrossRef] [PubMed]
63. White, R.L.; Burgess, D.S.; Manduru, M.; Bosso, J.A. Comparison of three different in vitro methods of
detecting synergy: Time-kill, checkerboard, and E test. Antimicrob. Agents Chemother. 1996, 40, 1914–1918.
[PubMed]
64. Hsieh, M.H.; Yu, C.M.; Yu, V.L.; Chow, J.W. Synergy assessed by checkerboard. A critical analysis. Diagn. Microbiol.
Infect. Dis. 1993, 16, 343–349. [CrossRef]
Pharmaceuticals 2018, 11, 34 18 of 25
65. Nilsson, A.S. Phage therapy—Constraints and possibilities. Ups. J. Med. Sci. 2014, 119, 192–198. [CrossRef]
[PubMed]
66. GRAS Notice (GRN) No. 672. Available online: https://www.accessdata.fda.gov/scripts/fdcc/?set=
grasnotices&id=672 (accessed on 19 March 2018).
67. Strickley, R.G. Solubilizing Excipients in Oral and Injectable Formulations. Pharm. Res. 2004, 21, 201–230.
[CrossRef] [PubMed]
68. Pirnay, J.-P.; Merabishvili, M.; Raemdonck, H.V.; Vos, D.D.; Verbeken, G. Bacteriophage Production in
Compliance with Regulatory Requirements. In Bacteriophage Therapy; Methods in Molecular Biology;
Humana Press: New York, NY, USA, 2018; pp. 233–252, ISBN 978-1-4939-7394-1.
69. Rathore, A.S.; Winkle, H. Quality by design for biopharmaceuticals. Nat. Biotechnol. 2009, 27, 26–34.
[CrossRef] [PubMed]
70. Fauconnier, A. Guidelines for Bacteriophage Product Certification. Methods Mol. Biol. 2018, 1693, 253–268.
[CrossRef] [PubMed]
71. European Directorate for the Quality of Medicines (EDQM). European Pharmacopoeia, 7th ed.; EDQM:
Strasbourg, France, 2010; pp. 163–167, 519–520.
72. Merabishvili, M.; Pirnay, J.-P.; Vos, D.D. Guidelines to Compose an Ideal Bacteriophage Cocktail.
In Bacteriophage Therapy; Methods in Molecular Biology; Humana Press: New York, NY, USA, 2018; pp. 99–110,
ISBN 978-1-4939-7394-1.
73. Levin, B.R.; Bull, J.J. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2004, 2,
166–173. [CrossRef] [PubMed]
74. Shao, Y.; Wang, I.-N. Bacteriophage Adsorption Rate and Optimal Lysis Time. Genetics 2008, 180, 471–482.
[CrossRef] [PubMed]
75. Chan, B.K.; Abedon, S.T.; Loc-Carrillo, C. Phage cocktails and the future of phage therapy. Future Microbiol.
2013, 8, 769–783. [CrossRef] [PubMed]
76. Schmerer, M.; Molineux, I.J.; Bull, J.J. Synergy as a rationale for phage therapy using phage cocktails. PeerJ
2014, 2. [CrossRef] [PubMed]
77. Pereira, C.; Moreirinha, C.; Lewicka, M.; Almeida, P.; Clemente, C.; Cunha, Â.; Delgadillo, I.; Romalde, J.L.;
Nunes, M.L.; Almeida, A. Bacteriophages with potential to inactivate Salmonella Typhimurium: Use of
single phage suspensions and phage cocktails. Virus Res. 2016, 220, 179–192. [CrossRef] [PubMed]
78. Bull, J.J.; Gill, J.J. The habits of highly effective phages: Population dynamics as a framework for identifying
therapeutic phages. Front. Microbiol. 2014, 5. [CrossRef] [PubMed]
79. Wu, S.; Zachary, E.; Wells, K.; Loc-Carrillo, C. Phage Therapy: Future Inquiries. Postdoc J. J. Postdr. Res. Postdr. Aff.
2013, 1, 24–35. [CrossRef]
80. Oechslin, F.; Piccardi, P.; Mancini, S.; Gabard, J.; Moreillon, P.; Entenza, J.M.; Resch, G.; Que, Y.-A. Synergistic
Interaction between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis
and Reduces Virulence. J. Infect. Dis. 2017, 215, 703–712. [CrossRef] [PubMed]
81. Chhibber, S.; Shukla, A.; Kaur, S. Transfersomal Phage Cocktail Is an Effective Treatment against
Methicillin-Resistant Staphylococcus aureus-Mediated Skin and Soft Tissue Infections. Antimicrob. Agents Chemother.
2017, 61, e02146-16. [CrossRef] [PubMed]
82. Fu, W.; Forster, T.; Mayer, O.; Curtin, J.J.; Lehman, S.M.; Donlan, R.M. Bacteriophage Cocktail for the
Prevention of Biofilm Formation by Pseudomonas aeruginosa on Catheters in an In Vitro Model System.
Antimicrob. Agents Chemother. 2010, 54, 397–404. [CrossRef] [PubMed]
83. Heller, K.; Braun, V. Polymannose O-antigens of Escherichia coli, the binding sites for the reversible adsorption
of bacteriophage T5+ via the L-shaped tail fibers. J. Virol. 1982, 41, 222–227. [PubMed]
84. Wang, J.; Hofnung, M.; Charbit, A. The C-Terminal Portion of the Tail Fiber Protein of Bacteriophage Lambda
Is Responsible for Binding to LamB, Its Receptor at the Surface of Escherichia coli K-12. J. Bacteriol. 2000, 182,
508–512. [CrossRef] [PubMed]
85. Loessner, M.J.; Kramer, K.; Ebel, F.; Scherer, S. C-terminal domains of Listeria monocytogenes bacteriophage
murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall
carbohydrates. Mol. Microbiol. 2002, 44, 335–349. [CrossRef] [PubMed]
86. Wright, A.; Hawkins, C.H.; Anggård, E.E.; Harper, D.R. A controlled clinical trial of a therapeutic
bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary
report of efficacy. Clin. Otolaryngol. 2009, 34, 349–357. [CrossRef] [PubMed]
Pharmaceuticals 2018, 11, 34 19 of 25
87. Schooley, R.T.; Biswas, B.; Gill, J.J.; Hernandez-Morales, A.; Lancaster, J.; Lessor, L.; Barr, J.J.; Reed, S.L.; Rohwer, F.;
Benler, S.; et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a
Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob. Agents Chemother. 2017, 61.
[CrossRef] [PubMed]
88. Gu, J.; Liu, X.; Li, Y.; Han, W.; Lei, L.; Yang, Y.; Zhao, H.; Gao, Y.; Song, J.; Lu, R.; et al. A Method
for Generation Phage Cocktail with Great Therapeutic Potential. PLoS ONE 2012, 7, e31698. [CrossRef]
[PubMed]
89. Miller, R.W.; Skinner, E.J.; Sulakvelidze, A.; Mathis, G.F.; Hofacre, C.L. Bacteriophage therapy for control of
necrotic enteritis of broiler chickens experimentally infected with Clostridium perfringens. Avian Dis. 2010, 54,
33–40. [CrossRef] [PubMed]
90. Breyne, K.; Honaker, R.W.; Hobbs, Z.; Richter, M.; Z˙aczek, M.; Spangler, T.; Steenbrugge, J.; Lu, R.;
Kinkhabwala, A.; Marchon, B.; et al. Efficacy and Safety of a Bovine-Associated Staphylococcus aureus
Phage Cocktail in a Murine Model of Mastitis. Front. Microbiol. 2017, 8. [CrossRef] [PubMed]
91. Daikos, G.L.; Tsaousi, S.; Tzouvelekis, L.S.; Anyfantis, I.; Psichogiou, M.; Argyropoulou, A.; Stefanou, I.;
Sypsa, V.; Miriagou, V.; Nepka, M.; et al. Carbapenemase-Producing Klebsiella pneumoniae Bloodstream
Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems.
Antimicrob. Agents Chemother. 2014, 58, 2322–2328. [CrossRef] [PubMed]
92. Paul, M.; Carmeli, Y.; Durante-Mangoni, E.; Mouton, J.W.; Tacconelli, E.; Theuretzbacher, U.; Mussini, C.;
Leibovici, L. Combination therapy for carbapenem-resistant Gram-negative bacteria. J. Antimicrob. Chemother.
2014, 69, 2305–2309. [CrossRef] [PubMed]
93. Kern, W.V.; Marchetti, O.; Drgona, L.; Akan, H.; Aoun, M.; Akova, M.; de Bock, R.; Paesmans, M.; Viscoli, C.;
Calandra, T. Oral antibiotics for fever in low-risk neutropenic patients with cancer: A double-blind,
randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus
amoxicillin/clavulanic acid combination therapy—EORTC infectious diseases group trial XV. J. Clin. Oncol.
2013, 31, 1149–1156. [CrossRef] [PubMed]
94. López-Cortés, L.E.; Cisneros, J.M.; Fernández-Cuenca, F.; Bou, G.; Tomás, M.; Garnacho-Montero, J.;
Pascual, A.; Martínez-Martínez, L.; Vila, J.; Pachón, J.; et al. Monotherapy versus combination therapy
for sepsis due to multidrug-resistant Acinetobacter baumannii: Analysis of a multicentre prospective cohort.
J. Antimicrob. Chemother. 2014, 69, 3119–3126. [CrossRef] [PubMed]
95. Davis, J.S.; Sud, A.; O’Sullivan, M.V.N.; Robinson, J.O.; Ferguson, P.E.; Foo, H.; van Hal, S.J.; Ralph, A.P.;
Howden, B.P.; Binks, P.M.; et al. Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant
Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial. Clin. Infect. Dis. 2016, 62,
173–180. [CrossRef] [PubMed]
96. Vestergaard, M.; Paulander, W.; Marvig, R.L.; Clasen, J.; Jochumsen, N.; Molin, S.; Jelsbak, L.; Ingmer, H.;
Folkesson, A. Antibiotic combination therapy can select for broad-spectrum multidrug resistance in
Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 2016, 47, 48–55. [CrossRef] [PubMed]
97. Ryan, E.M.; Alkawareek, M.Y.; Donnelly, R.F.; Gilmore, B.F. Synergistic phage-antibiotic combinations for
the control of Escherichia coli biofilms in vitro. FEMS Immunol. Med. Microbiol. 2012, 65, 395–398. [CrossRef]
[PubMed]
98. Knezevic, P.; Curcin, S.; Aleksic, V.; Petrusic, M.; Vlaski, L. Phage-antibiotic synergism: A possible approach
to combatting Pseudomonas aeruginosa. Res. Microbiol. 2013, 164, 55–60. [CrossRef] [PubMed]
99. Kamal, F.; Dennis, J.J. Burkholderia cepacia Complex Phage-Antibiotic Synergy (PAS): Antibiotics Stimulate
Lytic Phage Activity. Appl. Environ. Microbiol. 2015, 81, 1132–1138. [CrossRef] [PubMed]
100. Tazzyman, S.J.; Hall, A.R. Lytic phages obscure the cost of antibiotic resistance in Escherichia coli. ISME J.
2015, 9, 809–820. [CrossRef] [PubMed]
101. Chan, B.K.; Sistrom, M.; Wertz, J.E.; Kortright, K.E.; Narayan, D.; Turner, P.E. Phage selection restores
antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 2016, 6, 26717. [CrossRef] [PubMed]
102. Becker, S.C.; Foster-Frey, J.; Donovan, D.M. The phage K lytic enzyme LysK and lysostaphin act synergistically
to kill MRSA. FEMS Microbiol. Lett. 2008, 287, 185–191. [CrossRef] [PubMed]
103. Schuch, R.; Lee, H.M.; Schneider, B.C.; Sauve, K.L.; Law, C.; Khan, B.K.; Rotolo, J.A.; Horiuchi, Y.; Couto, D.E.;
Raz, A.; et al. Combination Therapy With Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone
for Treating Methicillin-Resistant Staphylococcus aureus–Induced Murine Bacteremia. J. Infect. Dis. 2014.
[CrossRef] [PubMed]
Pharmaceuticals 2018, 11, 34 20 of 25
104. García, P.; Martínez, B.; Rodríguez, L.; Rodríguez, A. Synergy between the phage endolysin LysH5 and
nisin to kill Staphylococcus aureus in pasteurized milk. Int. J. Food Microbiol. 2010, 141, 151–155. [CrossRef]
[PubMed]
105. Johnson, L.S.; MacDougall, C.; Trivedi, K.K. The Legislative Momentum of Antimicrobial Stewardship:
The US Perspective. Curr. Treat. Options Infect. Dis. 2016, 2, 93–101. [CrossRef]
106. Barlam, T.F.; Cosgrove, S.E.; Abbo, L.M.; MacDougall, C.; Schuetz, A.N.; Septimus, E.J.; Srinivasan, A.;
Dellit, T.H.; Falck-Ytter, Y.T.; Fishman, N.O.; et al. Implementing an Antibiotic Stewardship Program:
Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of
America. Clin. Infect. Dis. 2016, 62, e51–e77. [CrossRef] [PubMed]
107. Speksnijder, D.C.; Mevius, D.J.; Bruschke, C.J.M.; Wagenaar, J. A. Reduction of Veterinary Antimicrobial Use
in the Netherlands. The Dutch Success Model. Zoonoses Public Health 2015, 62, 79–87. [CrossRef] [PubMed]
108. Brown, D.G.; Lister, T.; May-Dracka, T.L. New natural products as new leads for antibacterial drug discovery.
Bioorg. Med. Chem. Lett. 2014, 24, 413–418. [CrossRef] [PubMed]
109. Harvey, A.L.; Edrada-Ebel, R.; Quinn, R.J. The re-emergence of natural products for drug discovery in the
genomics era. Nat. Rev. Drug Discov. 2015, 14, 111–129. [CrossRef] [PubMed]
110. Pettus, K.; Sharpe, S.; Papp, J.R. In Vitro Assessment of Dual Drug Combinations to Inhibit Growth of
Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 2015, 59, 2443–2445. [CrossRef] [PubMed]
111. Toledo, P.V.M.; Aranha Junior, A.A.; Arend, L.N.; Ribeiro, V.; Zavascki, A.P.; Tuon, F.F. Activity of
antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill
assay. Antimicrob. Agents Chemother. 2015, 59, 4301–4304. [CrossRef] [PubMed]
112. Abbreviations. Antibiotic & Antimicrobial Resistance Surveillance. Available online: http://www.bsacsurv.
org/science/antimicrobials/ (accessed on 20 March 2018).
113. Torres-Barceló, C.; Arias-Sánchez, F.I.; Vasse, M.; Ramsayer, J.; Kaltz, O.; Hochberg, M.E. A Window of
Opportunity to Control the Bacterial Pathogen Pseudomonas aeruginosa Combining Antibiotics and Phages.
PLoS ONE 2014, 9, e106628. [CrossRef] [PubMed]
114. Comeau, A.M.; Tétart, F.; Trojet, S.N.; Prère, M.-F.; Krisch, H.M. Phage-Antibiotic Synergy (PAS): β-Lactam
and Quinolone Antibiotics Stimulate Virulent Phage Growth. PLoS ONE 2007, 2, e799. [CrossRef] [PubMed]
115. Verma, V.; Harjai, K.; Chhibber, S. Restricting ciprofloxacin-induced resistant variant formation in biofilm of
Klebsiella pneumoniae B5055 by complementary bacteriophage treatment. J. Antimicrob. Chemother. 2009, 64,
1212–1218. [CrossRef] [PubMed]
116. Chhibber, S.; Gupta, P.; Kaur, S. Bacteriophage as effective decolonising agent for elimination of MRSA from
anterior nares of BALB/c mice. BMC Microbiol. 2014, 14, 212. [CrossRef] [PubMed]
117. Djurkovic, S.; Loeffler, J.M.; Fischetti, V.A. Synergistic Killing of Streptococcus pneumoniae with the
Bacteriophage Lytic Enzyme Cpl-1 and Penicillin or Gentamicin Depends on the Level of Penicillin Resistance.
Antimicrob. Agents Chemother. 2005, 49, 1225–1228. [CrossRef] [PubMed]
118. Thummeepak, R.; Kitti, T.; Kunthalert, D.; Sitthisak, S. Enhanced Antibacterial Activity of Acinetobacter
baumannii Bacteriophage ØABP-01 Endolysin (LysABP-01) in Combination with Colistin. Front. Microbiol.
2016, 7. [CrossRef] [PubMed]
119. Ibarra-Sánchez, L.A.; Van Tassell, M.L.; Miller, M.J. Antimicrobial behavior of phage endolysin PlyP100 and
its synergy with nisin to control Listeria monocytogenes in Queso Fresco. Food Microbiol. 2018, 72, 128–134.
[CrossRef] [PubMed]
120. Chhibber, S.; Nag, D.; Bansal, S. Inhibiting biofilm formation by Klebsiella pneumoniae B5055 using an iron
antagonizing molecule and a bacteriophage. BMC Microbiol. 2013, 13, 174. [CrossRef] [PubMed]
121. Viazis, S.; Akhtar, M.; Feirtag, J.; Diez-Gonzalez, F. Reduction of Escherichia coli O157:H7 viability on leafy
green vegetables by treatment with a bacteriophage mixture and trans-cinnamaldehyde. Food Microbiol. 2011,
28, 149–157. [CrossRef] [PubMed]
122. Chibeu, A.; Agius, L.; Gao, A.; Sabour, P.M.; Kropinski, A.M.; Balamurugan, S. Efficacy of bacteriophage
LISTEX™P100 combined with chemical antimicrobials in reducing Listeria monocytogenes in cooked turkey
and roast beef. Int. J. Food Microbiol. 2013, 167, 208–214. [CrossRef] [PubMed]
123. Chang, Y.; Yoon, H.; Kang, D.-H.; Chang, P.-S.; Ryu, S. Endolysin LysSA97 is synergistic with carvacrol in
controlling Staphylococcus aureus in foods. Int. J. Food Microbiol. 2017, 244, 19–26. [CrossRef] [PubMed]
Pharmaceuticals 2018, 11, 34 21 of 25
124. Misiou, O.; van Nassau, T.J.; Lenz, C.A.; Vogel, R.F. The preservation of Listeria-critical foods by a
combination of endolysin and high hydrostatic pressure. Int. J. Food Microbiol. 2018, 266, 355–362. [CrossRef]
[PubMed]
125. Van Nassau, T.J.; Lenz, C.A.; Scherzinger, A.S.; Vogel, R.F. Combination of endolysins and high pressure to
inactivate Listeria monocytogenes. Food Microbiol. 2017, 68, 81–88. [CrossRef] [PubMed]
126. Oliveira, H.; Thiagarajan, V.; Walmagh, M.; Sillankorva, S.; Lavigne, R.; Neves-Petersen, M.T.; Kluskens, L.D.;
Azeredo, J. A Thermostable Salmonella Phage Endolysin, Lys68, with Broad Bactericidal Properties against
Gram-Negative Pathogens in Presence of Weak Acids. PLoS ONE 2014, 9, e108376. [CrossRef] [PubMed]
127. Cooper, R. Honey as an Effective Antimicrobial Treatment for Chronic Wounds: Is There a Place for It in
Modern Medicine? Available online: https://www.dovepress.com/honey-as-an-effective-antimicrobial-
treatment-for-chronic-wounds-is-th-peer-reviewed-fulltext-article-CWCMR (accessed on 19 March 2018).
128. Halstead, F.D.; Webber, M.A.; Rauf, M.; Burt, R.; Dryden, M.; Oppenheim, B.A. In vitro activity of an
engineered honey, medical-grade honeys, and antimicrobial wound dressings against biofilm-producing
clinical bacterial isolates. J. Wound Care 2016, 25, 93–102. [CrossRef] [PubMed]
129. Holland, L.C.; Norris, J.M. Medical grade honey in the management of chronic venous leg ulcers. Int. J. Surg.
2015, 20, 17–20. [CrossRef] [PubMed]
130. El-Kased, R.F.; Amer, R.I.; Attia, D.; Elmazar, M.M. Honey-based hydrogel: In vitro and comparative In vivo
evaluation for burn wound healing. Sci. Rep. 2017, 7. [CrossRef] [PubMed]
131. Hillitt, K.L.; Jenkins, R.E.; Spiller, O.B.; Beeton, M.L. Antimicrobial activity of Manuka honey against
antibiotic-resistant strains of the cell wall-free bacteria Ureaplasma parvum and Ureaplasma urealyticum.
Lett. Appl. Microbiol. 2016, 64, 198–202. [CrossRef] [PubMed]
132. Taormina, P.J.; Niemira, B.A.; Beuchat, L.R. Inhibitory activity of honey against foodborne pathogens as
influenced by the presence of hydrogen peroxide and level of antioxidant power. Int. J. Food Microbiol. 2001,
69, 217–225. [CrossRef]
133. Kwakman Paulus, H.S.; Zaat Sebastian, A.J. Antibacterial components of honey. IUBMB Life 2012, 64, 48–55.
[CrossRef] [PubMed]
134. Cooper, R.A.; Molan, P.C.; Harding, K.G. Antibacterial activity of honey against strains of Staphylococcus
aureus from infected wounds. J. R. Soc. Med. 1999, 92, 283–285. [CrossRef] [PubMed]
135. Estevinho, L.; Pereira, A.P.; Moreira, L.; Dias, L.G.; Pereira, E. Antioxidant and antimicrobial effects of
phenolic compounds extracts of Northeast Portugal honey. Food Chem. Toxicol. 2008, 46, 3774–3779.
[CrossRef] [PubMed]
136. Roberts, A.E.L.; Brown, H.L.; Jenkins, R.E. On the Antibacterial Effects of Manuka Honey: Mechanistic
Insights. Available online: https://www.dovepress.com/on-the-antibacterial-effects-of-manuka-honey-
mechanistic-insights-peer-reviewed-fulltext-article-RRB (accessed on 19 March 2018).
137. Ettayebi, K.; El Yamani, J.; Rossi-Hassani, B. Synergistic effects of nisin and thymol on antimicrobial activities
in Listeria monocytogenes and Bacillus subtilis. FEMS Microbiol. Lett. 2006, 183, 191–195. [CrossRef]
138. Donsì, F.; Ferrari, G. Essential oil nanoemulsions as antimicrobial agents in food. J. Biotechnol. 2016, 233,
106–120. [CrossRef] [PubMed]
139. Ghosh, A.; Ricke, S.C.; Almeida, G.; Gibson, K.E. Combined Application of Essential Oil Compounds
and Bacteriophage to Inhibit Growth of Staphylococcus aureus In Vitro. Curr. Microbiol. 2016, 72, 426–435.
[CrossRef] [PubMed]
140. Landry, E.F.; Zsigray, R.M. Effects of calcium on the lytic cycle of Bacillus subtilis phage 41c. J. Gen. Virol.
1980, 51, 125–135. [CrossRef] [PubMed]
141. Pham, M.; Mintz, E.A.; Nguyen, T.H. Deposition kinetics of bacteriophage MS2 to natural organic matter:
Role of divalent cations. J. Colloid Interface Sci. 2009, 338, 1–9. [CrossRef] [PubMed]
142. Chhibber, S.; Kaur, T.; Kaur, S. Essential role of calcium in the infection process of broad-spectrum
methicillin-resistant Staphylococcus aureus bacteriophage. J. Basic Microbiol. 2014, 54, 775–780. [CrossRef]
[PubMed]
143. Bandara, N.; Jo, J.; Ryu, S.; Kim, K.-P. Bacteriophages BCP1-1 and BCP8-2 require divalent cations for efficient
control of Bacillus cereus in fermented foods. Food Microbiol. 2012, 31, 9–16. [CrossRef] [PubMed]
144. Marrucho, I.M.; Branco, L.C.; Rebelo, L.P.N. Ionic liquids in pharmaceutical applications. Annu. Rev. Chem.
Biomol. Eng. 2014, 5, 527–546. [CrossRef] [PubMed]
Pharmaceuticals 2018, 11, 34 22 of 25
145. San, K.; Long, J.; Michels, C.A.; Gadura, N. Antimicrobial copper alloy surfaces are effective against
vegetative but not sporulated cells of gram-positive Bacillus subtilis. MicrobiologyOpen 2015, 4, 753–763.
[CrossRef] [PubMed]
146. Kohler, L.J.; Quirk, A.V.; Welkos, S.L.; Cote, C.K. Incorporating germination-induction into decontamination
strategies for bacterial spores. J. Appl. Microbiol. 2017. [CrossRef] [PubMed]
147. Nakonieczna, A.; Cooper, C.J.; Gryko, R. Bacteriophages and bacteriophage-derived endolysins as potential
therapeutics to combat Gram-positive spore forming bacteria. J. Appl. Microbiol. 2015, 119, 620–631.
[CrossRef] [PubMed]
148. Bishop, A.H. Germination and persistence of Bacillus anthracis and Bacillus thuringiensis in soil microcosms.
J. Appl. Microbiol. 2014, 117, 1274–1282. [CrossRef] [PubMed]
149. Negus, D.; Taylor, P.W. A poly-γ-(D)-glutamic acid depolymerase that degrades the protective capsule of
Bacillus anthracis. Mol. Microbiol. 2014, 91, 1136–1147. [CrossRef] [PubMed]
150. Yang, H.; Wang, D.-B.; Dong, Q.; Zhang, Z.; Cui, Z.; Deng, J.; Yu, J.; Zhang, X.-E.; Wei, H. Existence of separate
domains in lysin PlyG for recognizing Bacillus anthracis spores and vegetative cells. Antimicrob. Agents Chemother.
2012, 56, 5031–5039. [CrossRef] [PubMed]
151. Buhr, T.L.; Young, A.A.; Barnette, H.K.; Minter, Z.A.; Kennihan, N.L.; Johnson, C.A.; Bohmke, M.D.;
DePaola, M.; Cora-Laó, M.; Page, M.A. Test methods and response surface models for hot, humid air
decontamination of materials contaminated with dirty spores of Bacillus anthracis ∆Sterne and Bacillus
thuringiensis Al Hakam. J. Appl. Microbiol. 2015, 119, 1263–1277. [CrossRef] [PubMed]
152. Setlow, P. Germination of Spores of Bacillus Species: What We Know and Do Not Know. J. Bacteriol. 2014,
196, 1297–1305. [CrossRef] [PubMed]
153. Paredes-Sabja, D.; Torres, J.A.; Setlow, P.; Sarker, M.R. Clostridium perfringens spore germination:
Characterization of germinants and their receptors. J. Bacteriol. 2008, 190, 1190–1201. [CrossRef] [PubMed]
154. Wheeldon, L.J.; Worthington, T.; Lambert, P.A. Histidine acts as a co-germinant with glycine and taurocholate
for Clostridium difficile spores. J. Appl. Microbiol. 2011, 110, 987–994. [CrossRef] [PubMed]
155. Römling, U.; Balsalobre, C. Biofilm infections, their resilience to therapy and innovative treatment strategies.
J. Intern. Med. 2012, 272, 541–561. [CrossRef] [PubMed]
156. Bjarnsholt, T. The role of bacterial biofilms in chronic infections. APMIS Suppl. 2013, 121, 1–51. [CrossRef]
[PubMed]
157. Wolcott, R.; Costerton, J.W.; Raoult, D.; Cutler, S.J. The polymicrobial nature of biofilm infection.
Clin. Microbiol. Infect. 2013, 19, 107–112. [CrossRef] [PubMed]
158. Høiby, N.; Bjarnsholt, T.; Givskov, M.; Molin, S.; Ciofu, O. Antibiotic resistance of bacterial biofilms. Int. J.
Antimicrob. Agents 2010, 35, 322–332. [CrossRef] [PubMed]
159. Choi, O.; Yu, C.-P.; Esteban Fernández, G.; Hu, Z. Interactions of nanosilver with Escherichia coli cells in
planktonic and biofilm cultures. Water Res. 2010, 44, 6095–6103. [CrossRef] [PubMed]
160. González, A.G.; Shirokova, L.S.; Pokrovsky, O.S.; Emnova, E.E.; Martínez, R.E.; Santana-Casiano, J.M.;
González-Dávila, M.; Pokrovski, G.S. Adsorption of copper on Pseudomonas aureofaciens: Protective role of
surface exopolysaccharides. J. Colloid Interface Sci. 2010, 350, 305–314. [CrossRef] [PubMed]
161. Barr, J.J.; Auro, R.; Furlan, M.; Whiteson, K.L.; Erb, M.L.; Pogliano, J.; Stotland, A.; Wolkowicz, R.;
Cutting, A.S.; Doran, K.S.; et al. Bacteriophage adhering to mucus provide a non-host-derived immunity.
Proc. Natl. Acad. Sci. USA 2013, 110, 10771–10776. [CrossRef] [PubMed]
162. Tseng, B.S.; Zhang, W.; Harrison, J.J.; Quach, T.P.; Song, J.L.; Penterman, J.; Singh, P.K.; Chopp, D.L.;
Packman, A.I.; Parsek, M.R. The extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the
penetration of tobramycin. Environ. Microbiol. 2013, 15, 2865–2878. [CrossRef] [PubMed]
163. Yan, J.; Mao, J.; Mao, J.; Xie, J. Bacteriophage polysaccharide depolymerases and biomedical applications.
BioDrugs 2014, 28, 265–274. [CrossRef] [PubMed]
164. Shang, A.; Liu, Y.; Wang, J.; Mo, Z.; Li, G.; Mou, H. Complete nucleotide sequence of Klebsiella phage P13
and prediction of an EPS depolymerase gene. Virus Genes 2015, 50, 118–128. [CrossRef] [PubMed]
165. Latka, A.; Maciejewska, B.; Majkowska-Skrobek, G.; Briers, Y.; Drulis-Kawa, Z. Bacteriophage-encoded
virion-associated enzymes to overcome the carbohydrate barriers during the infection process. Appl. Microbiol.
Biotechnol. 2017, 101, 3103–3119. [CrossRef] [PubMed]
166. Cataldi, M.; Sblendorio, V.; Leo, A.; Piazza, O. Biofilm-dependent airway infections: A role for ambroxol?
Pulm. Pharmacol. Ther. 2014, 28, 98–108. [CrossRef] [PubMed]
Pharmaceuticals 2018, 11, 34 23 of 25
167. Zhao, T.; Liu, Y. N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa. BMC Microbiol. 2010,
10, 140. [CrossRef] [PubMed]
168. Hernandez-Morales, A.C.; Lessor, L.L.; Wood, T.L.; Migl, D.; Mijalis, E.M.; Russell, W.K.; Young, R.F.;
Gill, J.J. Genomic and Biochemical Characterization of Acinetobacter Podophage Petty Reveals a Novel Lysis
Mechanism and Tail-Associated Depolymerase Activity. J. Virol. 2018, JVI.01064-17. [CrossRef] [PubMed]
169. Lai, M.-J.; Chang, K.-C.; Huang, S.-W.; Luo, C.-H.; Chiou, P.-Y.; Wu, C.-C.; Lin, N.-T. The Tail
Associated Protein of Acinetobacter baumannii Phage ΦAB6 is the Host Specificity Determinant Possessing
Exopolysaccharide Depolymerase Activity. PLoS ONE 2016, 11, e0153361. [CrossRef] [PubMed]
170. Guo, Z.; Huang, J.; Yan, G.; Lei, L.; Wang, S.; Yu, L.; Zhou, L.; Gao, A.; Feng, X.; Han, W.; et al.
Identification and Characterization of Dpo42, a Novel Depolymerase Derived from the Escherichia coli
Phage vB_EcoM_ECOO78. Front. Microbiol. 2017, 8, 1460. [CrossRef] [PubMed]
171. Lin, H.; Paff, M.L.; Molineux, I.J.; Bull, J.J. Therapeutic Application of Phage Capsule Depolymerases against
K1, K5, and K30 Capsulated E. coli in Mice. Front. Microbiol. 2017, 8. [CrossRef] [PubMed]
172. Pan, Y.-J.; Lin, T.-L.; Chen, C.-C.; Tsai, Y.-T.; Cheng, Y.-H.; Chen, Y.-Y.; Hsieh, P.-F.; Lin, Y.-T.; Wang, J.-T.
Klebsiella Phage ΦK64-1 Encodes Multiple Depolymerases for Multiple Host Capsular Types. J. Virol. 2017,
91, e02457-16. [CrossRef] [PubMed]
173. Hsieh, P.-F.; Lin, H.-H.; Lin, T.-L.; Chen, Y.-Y.; Wang, J.-T. Two T7-like Bacteriophages, K5-2 and K5-4, Each
Encodes Two Capsule Depolymerases: Isolation and Functional Characterization. Sci. Rep. 2017, 7, 4624.
[CrossRef] [PubMed]
174. Pyra, A.; Brzozowska, E.; Pawlik, K.; Gamian, A.; Dauter, M.; Dauter, Z. Tail tubular protein A:
A dual-function tail protein of Klebsiella pneumoniae bacteriophage KP32. Sci. Rep. 2017, 7, 2223. [CrossRef]
[PubMed]
175. Born, Y.; Fieseler, L.; Klumpp, J.; Eugster, M.R.; Zurfluh, K.; Duffy, B.; Loessner, M.J. The tail-associated
depolymerase of Erwinia amylovora phage L1 mediates host cell adsorption and enzymatic capsule removal,
which can enhance infection by other phage. Environ. Microbiol. 2014, 16, 2168–2180. [CrossRef] [PubMed]
176. Kumari, S.; Harjai, K.; Chhibber, S. Bacteriophage versus antimicrobial agents for the treatment of murine
burn wound infection caused by Klebsiella pneumoniae B5055. J. Med. Microbiol. 2011, 60, 205–210. [CrossRef]
[PubMed]
177. Ma, Y.; Pacan, J.C.; Wang, Q.; Sabour, P.M.; Huang, X.; Xu, Y. Enhanced alginate microspheres as means of
oral delivery of bacteriophage for reducing Staphylococcus aureus intestinal carriage. Food Hydrocoll. 2012, 2,
434–440. [CrossRef]
178. Soto, M.J.; Retamales, J.; Palza, H.; Bastías, R. Encapsulation of specific Salmonella Enteritidis phage f3αSE
on alginate-spheres as a method for protection and dosification. Electron. J. Biotechnol. 2018, 31, 57–60.
[CrossRef]
179. Vinner, G.K.; Vladisavljevic´, G.T.; Clokie, M.R.J.; Malik, D.J. Microencapsulation of Clostridium difficile specific
bacteriophages using microfluidic glass capillary devices for colon delivery using pH triggered release.
PLoS ONE 2017, 12, e0186239. [CrossRef] [PubMed]
180. Hathaway, H.; Ajuebor, J.; Stephens, L.; Coffey, A.; Potter, U.; Sutton, J.M.; Jenkins, A.T.A. Thermally
triggered release of the bacteriophage endolysin CHAPK and the bacteriocin lysostaphin for the control of
methicillin resistant Staphylococcus aureus (MRSA). J. Control. Release 2017, 245, 108–115. [CrossRef] [PubMed]
181. Ryan, E.M.; Gorman, S.P.; Donnelly, R.F.; Gilmore, B.F. Recent advances in bacteriophage therapy: How delivery
routes, formulation, concentration and timing influence the success of phage therapy. J. Pharm. Pharmacol. 2011,
63, 1253–1264. [CrossRef] [PubMed]
182. Hathaway, H.; Milo, S.; Sutton, J.M.; Jenkins, T.A. Recent advances in therapeutic delivery systems of
bacteriophage and bacteriophage-encoded endolysins. Ther. Deliv. 2017, 8, 543–556. [CrossRef] [PubMed]
183. Bustamante, N.; Rico-Lastres, P.; García, E.; García, P.; Menéndez, M. Thermal Stability of Cpl-7 Endolysin
from the Streptococcus pneumoniae Bacteriophage Cp-7; Cell Wall-Targeting of Its CW_7 Motifs. PLoS ONE
2012, 7, e46654. [CrossRef] [PubMed]
184. Son, B.; Yun, J.; Lim, J.-A.; Shin, H.; Heu, S.; Ryu, S. Characterization of LysB4, an endolysin from the Bacillus
cereus-infecting bacteriophage B4. BMC Microbiol. 2012, 12, 33. [CrossRef] [PubMed]
185. Walmagh, M.; Boczkowska, B.; Grymonprez, B.; Briers, Y.; Drulis-Kawa, Z.; Lavigne, R. Characterization of
five novel endolysins from Gram-negative infecting bacteriophages. Appl. Microbiol. Biotechnol. 2013, 97,
4369–4375. [CrossRef] [PubMed]
Pharmaceuticals 2018, 11, 34 24 of 25
186. Malik, D.J.; Sokolov, I.J.; Vinner, G.K.; Mancuso, F.; Cinquerrui, S.; Vladisavljevic, G.T.; Clokie, M.R.J.;
Garton, N.J.; Stapley, A.G.F.; Kirpichnikova, A. Formulation, stabilisation and encapsulation of bacteriophage
for phage therapy. Adv. Colloid Interface Sci. 2017, 249, 100–133. [CrossRef] [PubMed]
187. Pati, R.; Sahu, R.; Panda, J.; Sonawane, A. Encapsulation of zinc-rifampicin complex into
transferrin-conjugated silver quantum-dots improves its antimycobacterial activity and stability and
facilitates drug delivery into macrophages. Sci. Rep. 2016, 6, 24184. [CrossRef] [PubMed]
188. Leung, S.S.Y.; Parumasivam, T.; Gao, F.G.; Carrigy, N.B.; Vehring, R.; Finlay, W.H.; Morales, S.; Britton, W.J.;
Kutter, E.; Chan, H.-K. Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray
Drying Techniques for Treatment of Respiratory Infections. Pharm. Res. 2016, 33, 1486–1496. [CrossRef]
[PubMed]
189. Leung, S.S.Y.; Parumasivam, T.; Gao, F.G.; Carter, E.A.; Carrigy, N.B.; Vehring, R.; Finlay, W.H.; Morales, S.;
Britton, W.J.; Kutter, E.; et al. Effects of storage conditions on the stability of spray dried, inhalable
bacteriophage powders. Int. J. Pharm. 2017, 521, 141–149. [CrossRef] [PubMed]
190. Niwa, K.; Takaya, T.; Morimoto, T.; Takada, K. Preparation and evaluation of a time-controlled release capsule
made of ethylcellulose for colon delivery of drugs. J. Drug Target. 1995, 3, 83–89. [CrossRef] [PubMed]
191. Amabile, C.M.; Bowman, B.J. Overview of Oral Modified-Release Opioid Products for the Management of
Chronic Pain. Ann. Pharmacother. 2006, 40, 1327–1335. [CrossRef] [PubMed]
192. Shargel, L.; Andrew, B.; Wu-Pong, S. Applied Biopharmaceutics & Pharmacokinetics; McGraw-Hill Medical
Publishing Division: New York, NY, USA, 2015; pp. 119–120.
193. Fukuda, K.; Ishida, W.; Uchiyama, J.; Rashel, M.; Kato, S.; Morita, T.; Muraoka, A.; Sumi, T.; Matsuzaki, S.;
Daibata, M.; et al. Pseudomonas aeruginosa Keratitis in Mice: Effects of Topical Bacteriophage KPP12
Administration. PLoS ONE 2012, 7, e47742. [CrossRef] [PubMed]
194. Sarker, S.A.; McCallin, S.; Barretto, C.; Berger, B.; Pittet, A.-C.; Sultana, S.; Krause, L.; Huq, S.; Bibiloni, R.;
Bruttin, A.; et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh.
Virology 2012, 434, 222–232. [CrossRef] [PubMed]
195. McCallin, S.; Alam, S.S.; Barretto, C.; Sultana, S.; Berger, B.; Huq, S.; Krause, L.; Bibiloni, R.; Schmitt, B.;
Reuteler, G.; et al. Safety analysis of a Russian phage cocktail: From metagenomic analysis to oral application
in healthy human subjects. Virology 2013, 443, 187–196. [CrossRef] [PubMed]
196. Sarker, S.A.; Sultana, S.; Reuteler, G.; Moine, D.; Descombes, P.; Charton, F.; Bourdin, G.; McCallin, S.;
Ngom-Bru, C.; Neville, T.; et al. Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage
Preparations: A Randomized Trial in Children From Bangladesh. EBioMedicine 2016, 4, 124–137. [CrossRef]
[PubMed]
197. Xu, S.; Nie, Z.; Seo, M.; Lewis, P.; Kumacheva, E.; Stone, H.A.; Garstecki, P.; Weibel, D.B.; Gitlin, I.;
Whitesides, G.M. Generation of Monodisperse Particles by Using Microfluidics: Control over Size, Shape,
and Composition. Angew. Chem. 2005, 44, 724–728. [CrossRef] [PubMed]
198. Yousefi, M.; Inthavong, K.; Tu, J. Effect of Pressurized Metered Dose Inhaler Spray Characteristics and
Particle Size Distribution on Drug Delivery Efficiency. J. Aerosol Med. Pulm. Drug Deliv. 2017, 30, 359–372.
[CrossRef] [PubMed]
199. Griesang, F.; Decaro, R.A.; dos Santos, C.A.M.; Santos, E.S.; de Lima Roque, N.H.; da Costa Ferreira, M. How
Much Do Adjuvant and Nozzles Models Reduce the Spraying Drift? Drift in Agricultural Spraying. Am. J.
Plant Sci. 2017, 8, 2785. [CrossRef]
200. Dufour, N.; Delattre, R.; Ricard, J.-D.; Debarbieux, L. The Lysis of Pathogenic Escherichia coli by Bacteriophages
Releases Less Endotoxin Than by β-Lactams. Clin. Infect. Dis. 2017, 64, 1582–1588. [CrossRef] [PubMed]
201. Wang, Y.; Mi, Z.; Niu, W.; An, X.; Yuan, X.; Liu, H.; Li, P.; Liu, Y.; Feng, Y.; Huang, Y.; et al. Intranasal treatment
with bacteriophage rescues mice from Acinetobacter baumannii-mediated pneumonia. Future Microbiol. 2016,
11, 631–641. [CrossRef] [PubMed]
202. Duplessis, C.; Biswas, B.; Hanisch, B.; Perkins, M.; Henry, M.; Quinones, J.; Wolfe, D.; Estrella, L.; Hamilton, T.
Refractory Pseudomonas Bacteremia in a 2-Year-Old Sterilized by Bacteriophage Therapy. J. Pediatr. Infect.
Dis. Soc. 2017. [CrossRef] [PubMed]
203. Verheust, C.; Goossens, M.; Pauwels, K.; Breyer, D. Biosafety aspects of modified vaccinia virus Ankara
(MVA)-based vectors used for gene therapy or vaccination. Vaccine 2012, 30, 2623–2632. [CrossRef] [PubMed]
Pharmaceuticals 2018, 11, 34 25 of 25
204. Cho, S.-Y.; Park, S.-J.; Kwon, M.-J.; Jeong, T.-S.; Bok, S.-H.; Choi, W.-Y.; Jeong, W.-I.; Ryu, S.-Y.; Do, S.-H.;
Lee, C.-S.; et al. Quercetin suppresses proinflammatory cytokines production through MAP kinases and
NF-kappaB pathway in lipopolysaccharide-stimulated macrophage. Mol. Cell. Biochem. 2003, 243, 153–160.
[CrossRef] [PubMed]
205. Vallespi, M.G.; Alvarez-Obregón, J.C.; Rodriguez-Alonso, I.; Montero, T.; Garay, H.; Reyes, O.; Araña, M.J.
A Limulus anti-LPS factor-derived peptide modulates cytokine gene expression and promotes resolution of
bacterial acute infection in mice. Int. Immunopharmacol. 2003, 3, 247–256. [CrossRef]
206. David, S.A.; Silverstein, R.; Amura, C.R.; Kielian, T.; Morrison, D.C. Lipopolyamines: Novel Antiendotoxin
Compounds That Reduce Mortality in Experimental Sepsis Caused by Gram-Negative Bacteria. Antimicrob.
Agents Chemother. 1999, 43, 912–919. [PubMed]
207. Hu, Y.; Mao, A.; Yu, Z.; He, K. Anti-endotoxin and anti-inflammatory effects of Chinese herbal medicinal
alkaloid ingredients in vivo. Microb. Pathog. 2016, 99, 51–55. [CrossRef] [PubMed]
208. Kim, K.-P.; Cha, J.-D.; Jang, E.-H.; Klumpp, J.; Hagens, S.; Hardt, W.-D.; Lee, K.-Y.; Loessner, M.J.
PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response.
Microb. Biotechnol. 2008, 1, 247–257. [CrossRef] [PubMed]
209. Goodridge, L.D. Designing Phage Therapeutics. Available online: http://www.eurekaselect.com/71081/
article (accessed on 19 March 2018).
210. Resch, G.; Moreillon, P.; Fischetti, V.A. PEGylating a bacteriophage endolysin inhibits its bactericidal activity.
AMB Express 2011, 1, 29. [CrossRef] [PubMed]
211. Golshahi, L.; Lynch, K.H.; Dennis, J.J.; Finlay, W.H. In vitro lung delivery of bacteriophages KS4-M and
ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa
infections in cystic fibrosis. J. Appl. Microbiol. 2011, 110, 106–117. [CrossRef] [PubMed]
212. Fish, R.; Kutter, E.; Wheat, G.; Blasdel, B.; Kutateladze, M.; Kuhl, S. Bacteriophage treatment of intransigent
diabetic toe ulcers: A case series. J. Wound Care 2016, 25 (Suppl. 7), S27–S33. [CrossRef] [PubMed]
213. Uimajuridze, A.; Jvania, G.; Chanishvili, N.; Goderdzishvili, M.; Sybesma, W.; Managadze, L.; Chkhotua, A.;
Kessler, T. 265 Phage therapy for the treatment for urinary tract infection: Results of in-vitro screenings and
in-vivo application using commercially available bacteriophage cocktails. Eur. Urol. Suppl. 2016, 15, e265.
[CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
